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A B S T R A C T
Background
There is a trend towards greater patient involvement in healthcare decisions. Adequate discussion of the risks and benefits associated
with different choices is often required if involvement is to be genuine and effective. Achieving both the adequate involvement of
consumers and informed decision making are now seen as important goals for any screening programme. Personalised risk estimates
have been shown to be effectivemethods of risk communication in general, but the effectiveness of different strategies has not previously
been examined.
Objectives
To assess the effects of different types of personalised risk communication for consumers making decisions about taking screening tests.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2004), MEDLINE (1985
to December 2005), EMBASE (1985 to December 2005), CINAHL (1985 to December 2005), and PsycINFO (1989 to December
2005). Follow-up searches involved hand searching Preventive Medicine, citation searches on seven authors, and searching reference lists
of articles. For the original version of this review (Edwards 2003c) we also searched CancerLit (1985 to 2001) and Science Citation
Index Expanded (searched March 2002).
Selection criteria
Randomised controlled trials addressing the decisionby consumers ofwhether or not to undergo screening, incorporating an intervention
with a ’personalised risk communication element’ and reporting cognitive, affective, or behavioural outcomes. A ’personalised risk
communication element’ is based on the individual’s own risk factors for a condition (such as age or family history). It may be calculated
from an individual’s risk factors using formulae derived from epidemiological data, and presented as an absolute or relative risk or as a
risk score, or it may be categorised into, for example, high, medium or low risk groups. It may be less detailed still, involving a listing,
for example, of a consumer’s risk factors as a focus for discussion and intervention.
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Data collection and analysis
Two authors independently assessed each trial for quality and extracted data. We extracted data about the nature and setting of the
intervention, and relevant outcome data, along with items relating to methodological quality. We then used standard statistical methods
of the Consumers and Communication Review Group to combine data using MetaView, including analysis according to different levels
of detail of personalised risk communication, different condition for screening, and studies based only on high risk participants rather
than people at ’average’ risk.
Main results
Twenty-two studies were included, nine of which were added in the 2006 update of this review. There was weak evidence, consistent
with a small effect, that personalised risk communication (whether written, spoken or visually presented) increases uptake of screening
tests (odds ratio (OR) 1.31 (random effects, 95% confidence interval (CI) 0.98 to 1.77). In three studies the interventions showed
a trend towards more accurate risk perception (OR 1.65 (95% CI 0.96 to 2.81), and three other trials with heterogenous outcome
measures showed improvements in knowledge with personalised risk interventions. There was little other evidence from these studies
that the interventions promoted or achieved informed decision making by consumers about participation in screening. More detailed
personalised risk communicationmay be associatedwith a smaller increase in uptake of tests. That is, for personalised risk communication
which used and presented numerical calculations of risk, the OR for test uptake was 0.82 (95% CI 0.65 to 1.03). For risk estimates
or calculations which were categorised into high, medium or low strata of risk, the OR was 1.42 (95% CI 1.07 to 1.89). For risk
communication that simply listed personal risk factors the OR was 1.42 (95% CI 0.95 to 2.12).
Over half of the included studies assessed interventions in the context of mammography. These studies showed similar effects to the
overall dataset. The five studies examining risk communication in high risk individuals (individuals at higher risk due to, for example, a
family history of breast cancer or other conditions) showed larger odds ratios for uptake of tests than the other studies (random effects
OR 1.74; 95% CI 1.05 to 2.88).
There were insufficient data from the included studies to report odds ratios on other key outcomes such as: intention to take tests,
anxiety, satisfaction with decisions, decisional conflict, knowledge and resource use.
Authors’ conclusions
Personalised risk communication (as currently implemented in the included studies) may have a small effect on increasing uptake of
screening tests, and there is only limited evidence that the interventions have promoted or achieved informed decision making by
consumers.
P L A I N L A N G U A G E S U M M A R Y
Personalised risk information for helping people make an informed decision about taking screening tests
Screening tests aim to identify people who may have a particular disease or condition. People considering participation in screening
may receive information about the general risk of having the disease or condition, or information that is tailored to their personal
risk status (personalised risk information). This updated review of trials found that people given personalised risk information may
be more likely to participate in screening. However, there is not enough evidence to show whether people given personalised risk
information are making more informed decisions. Providing risk information in ways that better inform people may sometimes lead
to lower participation rates in screening.
B A C K G R O U N D
A variety of tests and procedures can be used to identify individuals
and groups at ’high risk’ of various diseases or conditions. Many
of these tests and procedures form part of screening programs -
programs with the objective of sorting out apparently well persons
who probably have a disease from those who probably do not.
They may only highlight a risk of disease, and are not intended to
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definitely diagnose a disease or condition.
Understanding is still limited of how best to present and discuss
risks and benefits of health care in general, and screening in partic-
ular, for an individual. Some screening programs provide informa-
tion about population or ’average’ risks of contracting a disease as a
basis for discussion or decision-making about undergoing screen-
ing, or perhaps more simply to try to motivate people to attend
for tests which are perceived by authorities to be in their or the
population’s best interests (Slaytor 1998). Others aim to provide
information which is more personally relevant to the consumer
in question. The latter is what we describe as ’personalised risk
communication’, sometimes also described as ’individualised risk
communication’. This may be based on the individual’s own risk
factors for a condition (such as age or family history). In some
cases it is calculated from an individual’s risk factors using formu-
lae derived from epidemiological data, with the information pre-
sented as an absolute risk or as a risk score, or categorised into, for
example, high, medium or low risk groups. It may be less detailed,
involving a listing, for example, of a consumer’s risk factors as a
focus for discussion and intervention. In these scenarios, it is gen-
erally anticipated that because the information is thought to be
more pertinent to the individual, personalised risk communica-
tion is more likely to be useful in decision-making about whether
or not to participate in screening.
Personalised risk communication has been incorporated into sev-
eral healthcare interventions, including the areas of treatment, pre-
vention and screening (Edwards 2000a). In view of the increase in
screening programs in health care, and the growing awareness that
consumer decisions can be influenced by the way risk informa-
tion is presented (Sarfati 1998; Edwards 2001), this review focuses
on the effects of personalised risk communication on consumers
making decisions about taking screening tests. The effects may be
varied. They include influences on ’cognitive’ outcomes such as
consumer knowledge or risk perception, ’affective’ outcomes such
as anxiety, and behavioural outcomes such as uptake of screening
tests (Llewelyn-Thomas 1995; Edwards 1999).
Concern about reaching set participation targets can lead to over-
zealousness on the part of healthcare providers, and a disregard
of ethics of good medical practice. Foster and Anderson (Foster
1998) criticise the implementers of the UK’s National Cervical
Screening Programme, including general practitioners, for their
persuasive tactics in getting patients to comply. They stress that
women should be made aware of the risks (discomfort, over-treat-
ment of abnormal smears) and limitations (false positives; false
negatives), as well as the benefits of the test. They also point out
that people have different risks of contracting the disease, based
on factors such as age, sexual activity, social class and smoking. In
contrast, some of the harms relating to screening tests are equi-
tably distributed among the population being screened - the risk
of direct harm from having a screening test for example. Other
harms, such as failure to detect disease, only apply to those with
the condition. In either scenario of harm, however, Raffle (Raffle
2001) warns that ’harm to uninformed participants leads to anger,
bitterness, and potentially to litigation’. Thus, the social and psy-
chological costs of screening need to be assessed (Stewart-Brown
1997). There is increasing attention to the issue of achieving and
demonstrating informed decision making about whether or not to
undergo screening. The UK has recently introduced the ’Prostate
Cancer Risk Management Programme’ which makes the Prostate
Specific Antigen (PSA) test available to all men who have received
information about the test and make an informed decision to take
the test. There is also a measure available for assessing informed
choice in Down’s Syndrome screening or testing (Marteau 2001),
but more work is required to produce measures for other condi-
tions if this type of outcome is to be widely reported in the litera-
ture.
Increasingly, the outcomes described in the literature also include
such ’affective’measures as satisfactionwith the decisionmade, and
’decisional conflict’. This includes whether an individual feels a de-
cision is consistent with their personal values, and certainty about
making the right decision (Llewelyn-Thomas 1995; O’Connor
1995; Holmes-Rovner 1996; Edwards 1999). There is also recog-
nition that uptake of tests per se is not necessarily desirable (for
example, prostate specific antigen screening and antenatal cys-
tic fibrosis screening are contentious areas). Making an informed
choice about entering screening, and adherence to the consumer’s
chosen option, are widely regarded as more desirable goals for risk
communication (Liao 1996; Sarfati 1998; Edwards 1999).
Risk communication itself may be subdivided by the dyad in-
volved (for example between agencies and the public, or from in-
dividual communicators), as well as according to the nature of the
risk, which may be familiar or non-familiar (Vlek 1987). Reviews
of ’mass’ risk communication, primarily from the environmental
health discipline (Fischhoff 1979; Covello 1986; Keeney 1986),
and from narrow clinical fields such as familial cancer (Bottorff
1996), are available. Briss 2004 also reviewed interventions that
sought to promote informed decisions about cancer screening, but
not through ’personalising’ risk information. In addressing the ef-
fects of personalised methods of risk communication this review
focuses on risk communication which is provided, used and evalu-
ated in healthcare encounters with individuals, couples, or imme-
diate families (for example, parents of young children). As such,
the review is broader than previous clinical risk communication
reviews (Bottorff 1996) but still aims to be relevant to the com-
munity and the clinical needs of healthcare professionals across a
range of disciplines. It focuses on the domain of healthcare screen-
ing.
This review updates the 2003 version, which identified thirteen
relevant studies (Edwards 2003c).
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O B J E C T I V E S
To compare the effects of personalised and general risk commu-
nication in deciding whether to participate in health screening,
on people’s cognitive, affective and behavioural outcomes. These
include their knowledge, risk perception, satisfaction with deci-
sion-making and decisional conflict, emotional wellbeing and be-
haviour (ie. taking screening tests).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs). Studies which were not un-
dertaken on the basis of ’intention to treat’ were not excluded, but
with weaker methodological quality less weight is attached to their
findings (Edwards 2000b).
Types of participants
People facing real life decisions (not hypothetical exercises) about
whether to undergo screening. They may be individuals making
decisions alone or on another’s behalf (for example, for a young
child), or couples making decisions together.
The screening activities must involve an investigation performed
by a health professional. Examples of these are (not an exhaustive
list):
• mammography;
• cervical ’Papanicolaou’ smears;
• colorectal cancer screening;
• prostatic cancer screening (PSA test);
• antenatal screening (including Down’s syndrome, neural
tube defects and other fetal anomalies);
• genetic screening (including breast cancer gene testing);
• high cholesterol / cardiovascular risk screening;
• neonatal screening (including cystic fibrosis and Duchenne
testing).
Studies to be excluded if they describe only:
• mass communication;
• military or school or prison-based interventions (where
consumers are less free to choose than in other healthcare
settings).
Types of interventions
The interventions are personalised risk information: individu-
alised risk score or individual actual risk information (absolute or
relative risk information); or categorisations of risk status based
on these estimates (for example, high, medium or low risk status);
or discussion of personal risk factors relevant to the screening de-
cision (that is, the individual’s own characteristics are taken into
account in assessing their actual risk or elevated risk status relative
to others).
The interventions also address decision-making about screening
tests; that is, testing whose objective is the presumptive identifica-
tion of unrecognised disease or defect (including genetic markers
for disease) by the application of tests or other procedures, which
can be applied rapidly. These tests are intended to sort out appar-
ently well persons who may have a disease from those who prob-
ably do not, and they are not intended to be diagnostic (Wilson
1968; Rose 1978).
The risk communication intervention could come before screen-
ing, at the time of the screening intervention, or at the time of
counselling or promotion of screening. Personalised risk commu-
nication could be delivered via oral, written, video, or electronic
(internet or CD-ROM) media.
Personalised risk information is compared to generalised risk com-
munication interventions, including: population risk estimates,
general information on risk factors, or general encouragement to
acknowledge risks or change risk behaviour.
Studies were rejected if they simply evaluated health education/
promotion to reduce risk factors or increase adherence to screen-
ing, without discussion of risks and benefits of undergoing or not
undergoing screening; or if general rather than personalised risk
communication was the main basis of the intervention.
Types of outcome measures
The outcome measures focused on identifying changes in any of
the following key areas (Llewelyn-Thomas 1995; Edwards 1999),
if appropriate data were available:
• ’cognitive’ outcomes: knowledge of risk, accurate risk
perception;
• ’affective’ outcomes: anxiety/emotional wellbeing,
satisfaction with decisions made, decisional conflict, anxiety,
intention to take up screening;
• behavioural outcomes: uptake of tests, adherence to choice
regarding screening test, ’appropriate’ uptake;
• health status outcomes: specific status measures or quality
of life measures such as SF-36;
• economic outcomes: cost of intervention.
Search methods for identification of studies
Two authors searched the Cochrane Central Register of Con-
trolledTrials (CENTRAL),MEDLINE,EMBASE,CINAHLand
PsycINFO. The search strategies were developed from earlier work
by Matthews et al (Matthews 1999) and the first (2003) publica-
tion of this review (Edwards 2003b; Edwards 2003c), as well as
that used by Jepson et al (Jepson 2000) in their systematic review.
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It comprised three layers of search terms - keywords and medi-
cal subject headings (MeSH) - aimed at identifying articles about
screening involving counselling/education or risk specifically. The
goal was for high recall (sensitivity) of literature in the field of
risk communication in screening (which may therefore be at the
expense of precision (specificity). We searched databases in OVID
from 1985 onwards, as extensive pilot searching indicated preced-
ing years to have extremely low yields of literature in this field
(Matthews 1999).
Search strategies were tailored to the relevant databases, and as ap-
propriate used mainly subject headings (for example, MEDLINE,
CINAHL) or the equivalent translated textwords (for example,
EMBASE). ’Explode’ functions were used on all subject headings.
All search strategies are presented in Appendices.
For the first publication of this review (Edwards 2003b; Edwards
2003c) we also searched CancerLit (1985 to 2001) and Science
Citation Index Expanded (searched March 2002). Strategies are
available from the lead author upon request.
The electronic searches for the 2003 review and the 2006 review
update produced a combined total of 9643 titles and abstracts for
assessment. We also undertook a manual follow-up of references
from key publications and journals, and of key authors. This was
informed by the output of the electronic searches, targeting the
publications or authors encountered most frequently. Seven au-
thors were selected on the basis of frequent publications in the
initial search outputs: BK Rimer (141 references), C Lerman (117
references), MD Schwartz (89 references), V Champion (60 ref-
erences), MWKreuter (52 references), CS Skinner (30 references)
and R Bastani (28 references). These yielded no more included
studies, but provided a wealth of background information. Other
prominent reviews or review protocols in the field were accessed
to see if they had any further relevant work (published or unpub-
lished) (Jepson 2000; O’Connor 2003). One article was identified
which represents the closest this field has to a prospective trials
register (Oncology 1994), documenting 11 relevant USA research
programs. We also undertook citation index searches for these au-
thors.
Data collection and analysis
Two authors (AE and JD) independently made an initial selec-
tion of publications from search outputs (titles and abstracts). Dis-
agreements were resolved by discussion. In cases of doubt about
relevance to this review, we retrieved papers in full for final deci-
sion making. Papers rejected at this stage were circulated to other
members of the study group to review the decision.
Data extraction
We extracted and collated on a template key information from
all selected publications. Two authors (AE and SH or AE and
JD) analysed all papers. Extracted data included country of ori-
gin, health professional group involved, screening program and
patient group involved, setting, sample size, and key outcomes.
We extracted further data on differences in baseline risk for assess-
ment of effect modifiers. Consistency of assessment was checked
(quality control) by weighted kappa agreement scores. Specifi-
cally, we extracted data on the nature/design of the intervention.
This included the type of personalised risk communication in the
main intervention: estimate or calculation of numerical risk or
risk score; estimated or calculated risk categorised as, for exam-
ple, high, medium or low level of risk to consumer; or listing of
personal risk factors without estimate or calculation of risk level.
The nature of the intervention also covered whether specific coun-
selling or behavioural change strategies, or both, were included in
the risk communication intervention.
Outcome data extracted comprised the absolute changes in num-
bers between groups (for dichotomous variables), and the mean
change and standard deviation of the mean change (for contin-
uous variables). From these, we calculated odd ratios (ORs) for
dichotomous variables, and weighted mean differences (WMDs)
for continuous outcomes. We also recorded the statistical signifi-
cance of results.
We examined important effect modifiers on the changes in out-
come demonstrated, examining in particular, if the datawere avail-
able, for the influence of: screening program or condition, setting,
professional group involved, type of intervention, differences in
baseline risk, age, gender, and educational level.
We also extracted data to assess the quality of the study. Twomem-
bers of the study team (AE and SH or AE and JD) assessed all
studies against checklists, derived from those by Jadad 1996 and
the ’Method Score’ used in a wider review of the risk communi-
cation literature (Edwards 2000a). The principal elements used
for this review were allocation concealment, blinding of assessors,
and intention-to-treat analyses. We resolved differences in assess-
ment of publications by discussion. Relevant data on the quality
and results of studies are summarised in the table ’Characteristics
of Included Studies’ and the Analyses. Allocation concealment is
rated as follows:
• A: Adequate concealment;
• B: Unclear;
• C: Clearly inadequate concealment;
• D: Not used (no attempt at concealment).
Data Combination
Studies in this review derive from a heterogeneous group of screen-
ing programmes. Nevertheless the essential characteristic of the
risk communication interventions (personalised elements) ren-
dered data combination appropriate.We first examined studies for
qualitative synthesis. We then used standard statistical methods of
the Consumers and Communication Review Group to combine
data usingMetaView. Tests for heterogeneity were included. Sensi-
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tivity analyses involved analysing different sections of the data, for
example according to different condition for screening or studies
based only on high risk participants rather than people at ’average’
risk. The categorisation of personalised risk communication into
three levels of detail given to consumers was also used to examine
for evidence of different effect from heterogeneous groups of in-
terventions.
Insufficient data were provided in many studies to enable (raw)
data entry into MetaView. As there was some heterogeneity of the
studies in terms of the screening tests addressed, participants and
design of intervention, results from a random effectsmodel (which
gives a more conservative confidence interval on the estimate of
effect size) were examined and are presented in cases of borderline
significance - in addition to analysis using a fixed effects model.
Consumer participation
For the original publication of this review (Edwards 2003c) the
lead author participated in email discussion of drafts of the proto-
col by a four-member consumer advisory group, including mem-
bers from three countries (see Acknowledgements). The advisory
group was also consulted on the content of the full review. An
anonymous referee from a fourth country was involved by the
Cochrane Consumers and Communication Review Group during
the editorial process for the protocol.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Twenty-two studiesmet the inclusion criteria.Nine of these studies
were added during the 2006 update of this review (Bowen 2002;
Campbell 1997; Champion 2000a; Champion 2002; Champion
2003; Jibaja-Weiss 2003; Lipkus 2005; Rimer 2002; Skinner
2002).
Thirteen of the 22 studies described a personalised risk communi-
cation intervention formammography screening programmes and
a further four addressed breast cancer risk and gene testing. Three
addressed cervical screening, two (high) cholesterol screening, two
addressed colorectal cancer screening, and one addressed prostate
cancer screening (some covered more than one topic). As in the
wider literature on one-to-one risk communication in health care
(Edwards 2000a), most studies derived from the USA. The in-
terventions were delivered by a range of healthcare professionals,
ranging from physicians and nurses to staff specifically recruited
and trained for the intervention studies.
Four interventions included a calculated risk estimate, such as
from the Gail model for breast cancer risk (Gail 1989). Three
interventions included a categorisation of risk level, such as into
’high’, ’medium’ or ’low’ strata. Fifteen interventions included the
most basic level of ’personalised risk’, such as the listing of risk
factors pertinent to an individual.
Five of the studies overall were based on samples of people thought
or known to be at higher risk than average for the population.
Regarding outcomes reported, most studies (13) measured uptake
of screening as an outcome. Five measured changes in risk percep-
tion (or perceived susceptibility). Five also measured intention to
take tests. Beyond this there were only a few outcomes with rele-
vant or reliable data for extraction. Three studies measured knowl-
edge (different measures), two studies measured anxiety, and there
was a range of outcomes for which only one study provided data
such as for comprehension, and stages of change.
A range of studies were considered closely for inclusion but were
eventually excluded. Broadly these fell into two groups. Some ex-
amined personalised risk communication, but had either no con-
trol data or inadequate control data from which to draw data for
comparison. Others did not specifically examine personalised risk
communication. (See Characteristics of excluded studies).
The included studies described various types of interventions. We
present a brief description of the interventions and outcomes be-
low. (See also Characteristics of included studies).
Bastani 1999 described a tailored risk notification programme for
women aged over 30 with a family history of breast cancer, iden-
tified via their first degree relatives diagnosed with the disease.
Women from the same family were randomised as a unit into ei-
ther a control group, or an intervention group in which each per-
son received:
• a letter listing personal risk factors and classifying one as
being at either slightly, moderately or substantially higher risk
compared to women of the same age; and
• a generic booklet titled ’Taking Action’, giving information
on risk factors, as well as addressing the importance and process
of mammography. Importantly, it highlighted the benefits while
minimising the risks of the process, and provided counter-
arguments to common barriers to screening; and
• a notepad and bookmark with reminder messages.
This intervention was compared to a control group receiving a
general information booklet on breast cancer. Rates of mammog-
raphy based on self-report one year after the intervention were
65.2% in the intervention group compared to 57.7% in the con-
trol group, both of which had baseline compliance rates of about
55%. The intervention effect was greatest in those aged over 50
years.
Bowen 2002 evaluated the effects of risk counselling about breast
cancer (BRCA) genetic testing among women with a family his-
tory of breast cancer. During the counselling, each participant was
provided with a calculated estimate of her risk, based on both the
Gail and Claus model scores (Gail 1989). Among those receiving
the intervention individually (as opposed to groups) there was a
reduction in the numbers perceiving themselves as ’appropriate
6Personalised risk communication for informed decision making about taking screening tests (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
candidates’ for the test (72/105 (68.6%) versus 84/109 (77.0%)
in the control group). However, this did not lead to differences in
expressed interest in having the test itself (37/105 (35.2%) in the
intervention group versus 36/109 (33.0%) in the control group).
Campbell 1997 evaluated a computer based strategy aimed at in-
creasinguptake of cervical screening amongwomen registeredwith
Australian general practices. Risk factors, including if a woman
had not had a smear within the previous two years, were sum-
marised in printed format for study participants. Smear uptake
was 52/148 (35%) in the intervention group, and 33/124 (27%)
in the control group.
Champion 1994 studied women aged 35 years and older, with no
history of breast cancer. They were randomised into four groups:
1. control group;
2. belief intervention - involving counselling based on the
Health Belief Model variables;
3. information intervention - information about
mammography and correct screening intervals;
4. belief + information interventions.
Women in groups 2 and 4 received counselling from graduate
nursing research assistants that involved a discussion of individ-
ual risk factors if baseline data showed they had low susceptibil-
ity scores, ie. low perceived risks. For the purposes of this review,
results for groups 2 and 4 (which contained the risk communica-
tion component) were combined and compared against those of
groups 1 and 3. One year after the intervention, 117/147 (79.6%)
of people receiving the belief interventions were ’compliant’ with
recommendations for screening compared to 103/153 (67.3%) in
the other groups. (NB: women under 41 were regarded as compli-
ant even if they had not had mammography). Perceived suscepti-
bility to breast cancer was the only belief variable not to undergo a
significant change post-intervention, despite this being the focus
of the risk communication intervention.
Champion 1995 reported a similar study, but on women aged
40 years and over. In addition, they examined movement across
’stages of change’ (Prochaska 1992). Again, no statistically signifi-
cant differences in susceptibility scores were identified. The belief
interventions increased mammography compliance one year after
intervention (OR 1.96 for the belief-only group; OR 2.26 for the
belief/information group) [raw data not reported]. There was also
a net movement from lower to higher stages of change which was
greatest in the belief and belief/information groups.
Champion 2000a evaluated a tailored intervention to increase
compliance regarding mammography in low income African-
American aged 45 to 64 years. The ’tailoring’ comprised listing of
personal risk factors for those women for whom ’perceived suscep-
tibility’ was identified as a way of progressing their ’stage of adop-
tion’ (others focused on perceived benefits or removing barriers).
Uptake of mammography after one year was 105/139 (75.7%)
in the intervention group, compared with 99/139 (71.1%) in the
control group.
Champion 2002 also evaluated a tailored intervention based on
the Health Belief Model and Transtheoretical (stages of change)
model, this time with clinic or Health Maintenance Organisation
(HMO) members. The interventions included both telephone
counselling and mailed elements, with elements listing suscepti-
bility factors for breast cancer risk, and these were assessed in fac-
torial design. Each element appeared to increase uptake of mam-
mography (tailored telephone counselling: odds ratio (OR) 1.66
(95% confidence interval (CI) 1.12 to 2.46); tailored mailing OR
1.72; 95% CI 1.18 to 2.52). However absolute data on uptake
are not reported in the published version, and no response was
received to our attempt to contact study authors.
Champion 2003 evaluated a tailored intervention aimed at in-
creasing mammography uptake in older women. As in the pre-
vious study (Champion 2002) it included elements listing sus-
ceptibility factors for breast cancer risk, and also used a multiple
group design which was used to evaluate in-person, telephone and
mailed elements of the intervention. The telephone and in-person
groups were combined for data about the personalised risk com-
munication effects for this review. The intervention group had a
higher uptake of mammography at 6 months (111/242 (45.9%))
than the control group (34/134 (25.4%)).
Curry 1993 also used a four group design to examine the effect on
mammography uptake of a risk factor questionnaire and personal
risk invitation on women aged 50 years and over who were en-
rolled at an HMO. For the purposes of this review, we compared
the results of the two groups that received the questionnaire, one
followed by a general risk invitation, giving a generic list of risk
factors - the ’control’ - and the other by the personal risk invitation
(including a list of personal risk factors). Uptake of mammogra-
phy at one year after the intervention in the personal risk group
was 162/413 (39.2%), compared to 161/428 (37.6%) in the gen-
eral risk group. There were significantly higher participation rates
in the personalised group among women with a family history of
breast cancer (66.7% versus 42.9% in the control group).
Hutchison 1998 investigated the effect on cholesterol screening
uptake of a postal questionnaire appraising the risk of coronary
heart disease (CHD). People (aged 20 to 69) in the intervention
group were advised to go for a cholesterol test if their answer scores
were above a certain level. The control group received a health
questionnaire that determined whether they were at risk without
identifying the risk factors as related to CHD. Rate of cholesterol
screening during three months of follow up was 75/1544 (4.9%)
in the intervention group compared to 27/1603 (1.7%) in the
control. Specifically, screening uptake for those who met the cri-
teria, and were thus advised to have the tests, was 45/421 (10.7%;
intervention) versus 9/504 (1.8%; control).
Jibaja-Weiss 2003 used information from medical records data to
tailor messages for low income and minority women regarding
both breast and cervical screening uptake. Scheduling and actual
uptake of screening tests was lower among women receiving the
personalised risk intervention (for example, for mammography:
120/239 (50.2%) scheduled, 31/239 (13.0%) uptake) compared
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to the group receiving a standard letter appropriately formatted
(’personalised form’ letter: 157/239 (65.7%) scheduled, P = 0.001;
73/239 (30.5%) uptake, P < 0.001).
Kreuter 1996 used a three-group design to investigate the effec-
tiveness of Health Risk Assessments (HRAs) on facilitating a range
of behaviour changes including uptake of mammography, pap
smears and cholesterol tests. The ’typical HRA’ intervention con-
sisted of feedback of personal risk information, graphically and
numerically. People in an ’Enhanced HRA’ group also received
individually tailored behaviour change information. For the pur-
poses of this review, we used the data from the ’typical HRA’ versus
control, to assess the influence of the personalised risk communi-
cation, but the data from ’enhanced HRA’ are valuable for further
interpretation. Analysis only involved people (aged 18 to 75) who
were non-compliant at baseline but were at least contemplating be-
haviour change. In the typical HRA group, 10/36 (27.8%), 24/46
(52.2%) and 19/33 (57.6%) were compliant after intervention for
cholesterol, cervical and breast cancer screening respectively. This
compares to 16/40 (40%), 21/32 (65.6%) and 17/31 (54.8%) in
the control group (non-statistically significant changes). However,
there were some indications that enhanced HRA may have had a
greater effect (compared to control) with, for example, cholesterol
screening increasing to 16/30 (53.3%) after this intervention.
Lee 1991 conducted a study with American federal employees
aged 40 and above as subjects. The intervention group received a
colorectal cancer risk appraisal that included a statement of the in-
dividual’s risk (categorised as high, moderate or normal) compared
to their peer group, as well as general facts about colorectal cancer
and the importance and availability of the Faecal Occult Blood
(FOB) test. The control group received a simple information letter
on the availability of the FOB test at the work site clinic. Out-
comes were measured three months after the intervention. No sta-
tistically significant differences were observed between groups in
terms of knowledge and beliefs regarding colorectal cancer and the
FOB test [data not given]. A small rise in the proportion of people
in the intervention group taking the test was observed (12/139
(8.6%) versus 6/139 (4.3%) in the control group). Additionally,
62.6% (87/139) in the intervention group compared to 36.2%
(50/139) in the control group (OR = 3.18) described an intention
to get an FOB test within the next year.
Lerman 1995 investigated the effects of individualised breast can-
cer counselling, involving a discussion of personal risk factors and
presentation of individualised risk estimates in women aged 35
and older with a family history of the disease. The control group
received general health counselling. Three months after the in-
tervention, the subjects were assessed for an improvement in risk
comprehension. Those in the intervention group were more likely
to improve: 26% (23/90) versus 17% (19/110) (OR 3.5 (95% CI
1.3 to 9.5)); and this was more marked among African American
women. However, in both groups, about two thirds of women
continued to substantially overestimate their lifetime risks. In an
accompanying paper (Lerman 1996), the authors also report on
the impact of the risk counselling on breast-cancer-specific distress
and general distress. Risk counselling succeeded in significantly
reducing the former (P < 0.01), especially in women with less
formal education. The counselling did not affect general mood
distress. Schwartz 1999 determined mammography uptake in the
risk counselling group compared to the general counselling group
one year after intervention. The groups did not differ significantly
at baseline or followup. Among the less educatedwomen, those re-
ceiving risk counselling showed reduced mammography use (OR
0.44 (95% CI 0.23 to 0.83)).
Lerman 1997 also evaluated the impact of education and coun-
selling (more specifically addressing knowledge and decision-mak-
ing regarding BRCA1 testing) among women with a family his-
tory of breast and/or ovarian cancer. In addition to information on
the benefits, limitations and risks of testing, the educational inter-
vention involved a qualitative discussion of individual risk factors.
Women on the waiting list served as control subjects. Perceived
risk and testing intentions were measured at a one-month follow-
up. Education succeeded in reducing risk perceptions from an av-
erage score of 2.12 to 1.88 (range 1 to 4) compared to controls (P
< 0.05). There was no significant effect of education on intent to
undergo testing, with 57% (66/116) versus 53% (87/164) in the
control group stating that they would definitely or probably take
the test.
Lipkus 2005 examined a personalised (tailored) intervention for
carpentry workers, who have occupational risk factors for colorec-
tal cancer. Risk factors identified from a baseline survey were fed
back as part of an intervention seeking to modify people’s attribu-
tion of colorectal cancer risk, as a means of modifying perceptions
of risk and subsequent uptake of faecal occult blood (FOB) tests
for colorectal cancer screening. No significant changes in attribu-
tions or perceptions of risk were identified, suggesting that partic-
ipants did not integrate colorectal cancer risk factor information
into their conceptualisations of colorectal cancer risk. However,
uptake of FOB tests was higher in the intervention group (270/
432; 62.5%) compared with the control group (238/428; 55.6%),
suggesting that the intervention was effective at increasing the
overall screening rate, but that this had not been achieved by the
intended means of modifying CRC risk perceptions and worry.
Myers 1999 compared the effects of two interventions on Prostate
Specific Antigen (PSA) ’adherence’ in a sample of African Amer-
ican men aged 40 to 70 years. The minimal intervention group
(ie. ’control’ for the purposes of this review) received a letter of
invitation for free screening, as well as reminder calls and letters.
The enhanced intervention group received, in addition, a cultur-
ally sensitive educational booklet and a tailored (personal) risk fac-
tors and symptoms form based on information given by the men
in a baseline survey. Fifty-one per cent (98/192) of the risk inter-
vention group were defined as ’adherers’ after one year follow-up,
compared to 29% (64/221) in the control group.
Rimer 2002 investigated the effects of tailored print (TP) and
counselling compared to usual care on mammography uptake as
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well as perceptions of breast cancer risk, with female members of
an HMO aged in their 40s and 50s. The tailored print interven-
tion included a section on personal risk of developing breast can-
cer in the next ten years presented graphically and numerically.
Screening uptake one year after the intervention (Rimer 2001) in
the TP group was 52% (204/392) compared to 56% (231/412)
in the control, and 28% in the TP group had an accurate risk
perception (defined as not overestimating risk) compared to 25%
in the control. The group that received tailored print reinforced
with tailored counselling fared better in terms of accurate risk per-
ception (42%) and were also found to have higher mammography
rates of 61% (197/323). The personalised (tailored) intervention
effects of greater knowledge, more accurate risk perception and
lower screening test uptake were also sustained through to two
years of follow up (Rimer 2002).
Saywell 1999 compared the cost effectiveness of five interventions
to increase mammography screening. For the purposes of this re-
view, the combined results of the telephone and in-person coun-
selling groups (in which personal susceptibility was addressed de-
pending on a woman’s initial response) were compared to the con-
trol ’no counselling’ group. One month after the intervention,
the mammography ’compliance’ rates were 29% (68/237) in the
combined intervention group, counselled either by telephone or
in person, compared to 18.2% (20/110) in the control group.
Schwartz 1999 evaluated breast cancer risk counselling that in-
cluded elements of discussing risk factors, presenting individu-
alised risk estimates, and recommendations for mammography
use. Uptake of mammography was lower in the intervention group
(148/215; 69%) than in the control group (161/215; 75%) whose
intervention included assessment of current health practices, age-
specific screening recommendations and other general health rec-
ommendations (for example, for diet, exercise, smoking).
Skinner 1994 examined the effects of tailored letters (addressing
personal risk status, as well as beliefs and barriers, and taking into
account people’s stage of change) compared to standardised letters,
on recall and readership of information, and mammography stage
movement. The tailored letters were framed to sound as if they
were meant for general audiences, ie. not specifically for the indi-
vidual concerned, but were still based on risk calculation for the
individual woman. Women (aged 40 to 65) who received tailored
letters were more likely to remember them (P < 0.05). However,
there were no significant main effects for stage movement by letter
type. Forty-four per cent (33/76) of the tailored letter recipients
who were due for screening at baseline had a mammogram, com-
pared to 31% (24/76) in the standard letter group. The interven-
tion was most effective for African American and low income (<
US$26,000 per annum income) women.
Skinner 2002 also examined tailoring of pre-counselling materials
for breast cancer gene (BRCA) testing among women with a per-
sonal or family history of breast and/or ovarian cancer. Risk infor-
mation was converted into quartiles for level of risk. The person-
alised (tailored) intervention led to greater knowledge levels (24%
increase versus 16% for controls; P < 0.0001), and less over-esti-
mation of risk (40% versus 70% in controls; P < 0.0001). Anxiety
levels showed no differences between groups. Fewer participants
in the intervention group expressed intentions to take tests (87%)
than in the control group (97%; P < 0.05). Thus this study pro-
vides some evidence of the required elements for informed deci-
sion making (knowledge and accurately perceived risk), and with-
out potential harms (anxiety). There is some evidence that this
may diminish people’s intention to take tests, but the study has
not followed this through to evaluate effects on actual decision
making.
Risk of bias in included studies
The studies were of variable quality, but generally good, especially
in comparison to many other studies in the field of risk commu-
nication in health care (Edwards 2000a). However, few reports in
the literature showed evidence of adequate concealment of allo-
cation to randomisation groups in the trial concerned (adequate
in 2 studies (Champion 2003; Jibaja-Weiss 2003), inadequate in
1 study (Kreuter 1996) and unclear in 19 studies). Seven studies
analysed on an intention-to-treat basis, and 15 did not. Most stud-
ies were also unclear about the blinding of assessors in outcome
measures although many used patient-reported or objective mea-
sures for key outcomes such as assessing test uptake from comput-
erised registers.
Effects of interventions
Overall, there is weak evidence, consistent with a small effect, that
personalised risk communication (whether written, spoken, or vi-
sually presented) increases uptake of screening tests (fixed effects
OR 1.13 (95% CI 1.02 to 1.24); random effects OR 1.31 (95%
CI 0.98 to 1.77), see Analysis 1.9). In three studies the interven-
tions showed a trend towards more accurate risk perception (fixed
effects OR 1.46 (95% CI 1.13 to 1.88); random effects OR 1.65
(95% CI 0.96 to 2.81), see Analysis 1.4), and three other trials
with heterogenous outcome measures showed improvements in
knowledge with personalised risk interventions. There was little
other evidence from these studies that the interventions promoted
or achieved informed decision making by consumers about par-
ticipation in screening. One study assessed ’appropriate uptake’ of
tests (externally defined appropriateness: that is, uptake for people
at higher risk, and non-uptake for people at lower risk) and found
more appropriate uptake after the personalised risk intervention
(Hutchison 1998). Another study examined whether people per-
ceived themselves as appropriate for the tests after the interven-
tion, with a trend towards fewer people perceiving appropriate-
ness of tests after the intervention (but not statistically significant;
Bowen 2002). Skinner 2002 also showed that people were more
knowledgeable, and had more accurate perceptions of risk, but
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fewer people intended to take tests after the personalised risk in-
tervention.
Within this overall increase in uptake, more detailed personalised
risk communication may be associated with a smaller increase
in uptake of tests. That is, for personalised risk communication
which used and presented numerical calculations of risk, the OR
for test uptake was 0.82 (95% CI 0.65 to 1.03), (see Analysis
1.9 Subcategory 01). For risk estimates or calculations which were
categorised into high, medium or low strata of risk, the OR was
1.42 (95% CI 1.07 to 1.89), (see Analysis 1.9 Subcategory 02).
For risk communication that simply listed personal risk factors the
OR was 1.17 (95% CI 1.04 to 1.32) by fixed effects model and
1.42 (95% CI 0.95 to 2.12) by random effects model (see Analysis
1.9 Subcategory 03).
The results for the studies addressing mammography showed sim-
ilar effects to the overall dataset. The overall OR for an effect on
uptake of screening test was 1.11 (95% CI 0.98 to 1.24) by fixed
effects and 1.15 (95% CI 0.85 to 1.54) by random effects, but
with evidence of significant heterogeneity (P < 0.01). The numer-
ical calculated risk estimates were associated with lower ORs for
uptake of tests (OR 0.82 (95% CI 0.66 to 1.02)) compared to the
categorised risk estimates (OR 1.37 (95% CI 1.02 to 1.84)) or
lists of personal risk factors (fixed effects OR 1.22 (95% CI 1.04
to 1.43); random effects OR 1.30 (95% CI 0.81 to 2.07)). (See
Analysis 3.8 and subcategories).
The five studies examining risk communication in high risk in-
dividuals showed trends towards larger odds ratios for uptake of
tests than the other studies, though with heterogeneity (P < 0.01)
between the three levels of personalisation of risk communication.
The OR for numerical calculated risk estimates was 1.48 by fixed
effects (95% CI 1.06 to 2.07) and 2.16 by random effects (95%
CI 0.25 to 18.86). The OR for categorised estimates of risk was
1.37 (95% CI 1.02 to 1.84). The OR for listed personal risk fac-
tors was 1.49 by fixed effects (95% CI 1.16 to 1.91) and 1.77
by random effects (95% CI 0.91 to 3.42). (See Analysis 5.8 and
subcategories).
There were insufficient data from the included studies to report
odds ratios onother key outcomes such as: intention to take tests (5
studies but with significant heterogeneity, P < 0.01), anxiety, satis-
faction with decisions, decisional conflict, and knowledge. These
other outcomes generally had one or no studies with extractable
data (and so it is inappropriate to report confidence intervals).
No extractable data on costs, ’appropriate’ uptake, or health status
(other than anxiety) were identified.
D I S C U S S I O N
This review updates the first (2003) publication of this review
(Edwards 2003b; Edwards 2003c). There are still relatively few
studies in the field of screening that have examined the effects of
personalised risk communication. However, nine further studies
have been included in this revision and the results remain largely
consistent with the findings of the first review (Edwards 2003b;
Edwards 2003c). The studies that are available provide weak evi-
dence, consistent with a small effect, that personalised risk com-
munication (whether written, spoken or visually presented) in-
creases uptake of screening tests, but there is little evidence that
these interventions promote or achieve their effects by enhanc-
ing informed decision making by consumers. However, in the
same way that screening recommendations have developed in re-
cent years from simply seeking to maximise uptake, to promotion
of informed choice about participation in screening programmes
(Holland 2005), so the literature shows variation and some de-
velopment towards this also. Thus some more recent studies have
sought to address knowledge, perceived risk, and other elements
of informed decision making that are not evident in earlier studies
which sought rather simply to enhance consumers’ adherence to
screening recommendations. Some data suggest that when there
is greater detail of disclosed information in the personalised risk
communication with consumers, the uptake of tests is lower than
when the risk communication is less detailed or numerically spe-
cific.
The weaknesses of these data lie in the small number of studies.
Evidently this is still an emerging field and findings or hypothe-
ses that may emerge from these data require further evaluation
when more primary studies are available. The results are domi-
nated by findings from the topic area of mammography. Caution
is therefore required in generalising from these results in toto, and
particularly for clinical topics other than mammography. Against
this, the strength of these data lies in the fact that the studies have
been gleaned from systematic searches of several key databases and
contact with key authors in the field, and represent a synthesis of
the existing literature base.
The relative paucity of data in the screening area reflects the diffi-
culties for researchers or clinicians in providing personalised risk
communication for consumers. The range of clinical topics cov-
ered here is narrow. Calculation or estimation of risk is depen-
dent on adequate epidemiological background data, and feasible
means of converting this into information for individual con-
sumers based on their own risk factors. Examples include the Gail
model (Gail 1989) andmethods for calculating cardiovascular risk
(Heart 1999), but only the latter has permeated into routine clin-
ical practice. There is a need for equivalent epidemiological re-
search into an extended range of clinical topics. This could pro-
vide a basis for models that allow calculation of personalised risk
estimates for individuals about other conditions, such as cervical,
prostate or colorectal cancer. Then further evaluation of the ef-
fects of providing such personalised risk information to consumers
would be possible.
In the meantime, the pattern of the effects across the different
categories of personalised risk communication is challenging. It
suggests that the greater details offered by the interventions pro-
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viding calculated numerical risk estimates may lead to reduced test
uptake. These results can be placed in a context of other findings
from the field of risk communication, particularly those that relate
to the effects of framing and othermanipulations of data presenta-
tion (Edwards 2001). Those data suggest that whilst many persua-
sive effects of information presentation formats are evident, when
more data are provided to consumers, and in particular data that
are most relevant or pertinent to the decision in question, then
consumers become more wary of the treatments or tests on offer.
As above, this is not evidence of informed decision making per se,
but when the direction of effects is contrary to the apparent trend
in service provision then it suggests that the information may be
having a significant impact.With reference to the studies included
in this review, it may be that the most detailed levels of person-
alised risk information are more likely to contribute to informed
decision making - but this also is associated with lower uptake of
screening tests. The greater effects shown in the less specific levels
of personalised risk communication may suggest that these effects
reflect more the influence of the healthcare encounter - and the
conventional leaning towards promoting use of services (ie. tests
in this case) (Raffle 2001) - and are not necessarily evidence of
informed decision making by consumers.
High risk status an effect modifier
The effects of interventions on screening uptake appeared greater
among consumers or patients deemed to be at higher risk than
average. In this group of studies there was no evidence or trend
in the data to suggest differences in uptake between the interven-
tions using detailed calculations of risk estimates or more general
types of listing risk factors. This suggests that the ’high risk status’
of the consumer is an important effect modifier for personalised
risk communication. There appears to be potential for substantial
modification of choices made among this group of consumers. It
may be appropriate that the scope for interventions to influence
decisions is large in this group of consumers. But, equally, inter-
ventions could be potentially harmful if they are not introduced
carefully. Healthcare professionals must take steps to ensure that
they are achieving informed decision making by consumers.
Demonstrating informed choices
There may also be an onus on professionals to demonstrate this
informed decision making with evidence. Further research is re-
quired into how such informed decision making by consumers
can be demonstrated validly. There are some outcome measures
in this field such as the multi-dimensional measure of informed
choice in Down’s syndrome screening (Marteau 2001). This is
based on assessing the consistency between knowledge, attitudes
to tests and choices of uptake of tests. This measure is specific to
Down’s screening at present. Further research should explore the
development of measures for other screening choices, or whether a
generic measure of informed choice for screening decisions is feasi-
ble. This would require more general cognitive measures than the
condition-specific knowledge items. Other scales currently avail-
able offer the scope to derive such a cognitive component for a
generic measure (O’Connor 1995; Barry 1997; Edwards 2003a)
but at the present time, there is no validated measure of informed
choice in cancer screening (Jepson 2005).
Tensions between public health and individual health policy
Focusing on the achievement and demonstration of informed
choices, in isolation, would, nonetheless, fail to address the wider
context. This context concerns an apparent tensionbetweenpublic
health and individual health policy. Policies of greater patient in-
volvement in decisions are being pursued, and this is justified from
both ethical perspectives and some (though perhapsmore limited)
evidence of improved health outcomes (Guadagnoli 1998). There
is a need to evaluate whether such policies mean that those peo-
ple invited for screening are genuinely making informed choices,
and how comprehensive information affects other variables such
as uptake, cost effectiveness, and satisfaction (Jepson 2005). Ap-
propriate risk communication has an integral role in this (Elwyn
2000). But as this is followed through, it is likely that public health
objectives might be compromised. An example may be seen in
the case of cervical (Papanicolaou smear) screening. The absolute
benefits of Papanicolaou screening may be small for most women.
Most women are at very low risk of developing cervical cancer, but
they may perceive their risk to be higher as a result of the level of
screening activity, publicity and public health messages about the
importance of screening for the population. Some women may
choose not to have regular screening when informed of the abso-
lute levels of risk and benefit from the screening programme. But
the public healthmessage, aided sometimes by financial incentives
for clinicians to achieve high uptake figures, means that informed
decision making by patients is still a major challenge (Thomson
2005).
The same tension exists in relation to cardiovascular screening
(Marteau 2002). These tensions between public health goals and
individual choicesmust be recognised (Rogers 2002). An informed
debate should be conducted among the relevant interest groups
- government, public health, clinicians, and particularly patients
and patient representative groups. There are some signs that this
debate is now taking place (Marteau 2002). Policy developments
could explore whether individually appropriate choices, which
vary from those recommended by standards and guidelines, can
be accommodated in assessments of achieving best practice (ie.
meeting standards) at population level. One solution may be for
care to be viewed as ’adherent to guidelines’ or ’satisfactory’ if ade-
quate steps have been made to achieve and demonstrate informed
decision making by patients - even if it deviates from the conven-
tional (bio-medical) recommendations of those guidelines.
Taking the example of cervical cancer screening, a full discussion
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of the pros and cons of screening for cervical cancer may be viewed
as a satisfactory goal for the healthcare provider, even if an individ-
ual woman chooses not to undergo screening, thus against public
health advice. Counting such scenarios as satisfactory or adherent
to guidelines (for example for purposes of audit) may allow health-
care professionals to enhance their communication with patients.
If this is incorporated into the goals of health care then improve-
ments in care can be achieved without also falling foul of require-
ments for governance, audit, and payment targets. An example
was evident in the criteria for Fellowship by Assessment (FBA) of
the Royal College of General Practitioners (UK). In the case of
vaccination targets, the criteria stated that ’candidates who are un-
able to demonstrate these standards must exceed the average level
of vaccination and show how patients/parents/carers are enabled
to make an informed choice about vaccination’. The FBA scheme
has now been halted for wider revision (2006), but the issue of
informed decision making in preventive activities could equally
apply to screening choices. The need for measures to demonstrate
informed choice across a number of healthcare decisions is further
reiterated.
Broader research in this field
It is not only ’informed choice’ that is yet to be fully addressed
in this field. The data available are conspicuously loaded towards
assessment of screening uptake. Few studies have addressed and
have extractable data on other outcomes. These include the cog-
nitive measures, such as knowledge and risk perception, which
have been addressed more commonly in risk communication liter-
ature to date (Edwards 1999) and in studies of informed decision
making in cancer screening (Briss 2004). They also include the
affective measures that are increasingly advocated as a focus of re-
search (Llewelyn-Thomas 1995). These are the measures that are
likely to be more specific and perhaps more responsive to change
(Edwards 1999), but in particular come closest to addressing the
core constructs that build towards informed decision making by
consumers. Such measures include decisional conflict (O’Connor
1995), satisfaction with decision making (Holmes-Rovner 1996),
anxiety measures (Marteau 1992), and making decisions that are
consistent with individuals’ values and preferences. The use of such
outcome measures is sparse in the currently available literature
on personalised risk communication interventions and screening
studies more generally (Briss 2004). It is important that further
intervention studies in this field incorporate such measures into
their evaluations (Irwig 2006).
When such evaluations are available it would enable a clearer pic-
ture about the effects of personalised risk communication inter-
ventions to be drawn. A more rounded interpretation would be
possible, compared to the present in which data are only really in-
terpretable in relation to screening uptake. This should shed light
on how personalised risk information, which is often advocated
for or by consumers, is influencing decision making about screen-
ing choices in health care.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is weak evidence that personalised risk communication leads
to small increases in uptake of screening programmes. Even in
studies where increased uptake was demonstrated, and thus which
may meet professionally or policy driven agendas in health care,
it is not yet clear that the increased uptake is associated with in-
formed decision making by consumers. Until such evidence of
informed decision making is available it seems to be difficult to
support such interventions (as currently implemented). The ten-
sion between the public health policy and individual health policy
agendas should be recognised and debated by the relevant stake-
holders (consumers, professionals, policy makers and purchasers).
This debate should explore how to accommodate the tensions of
addressing both policy agendas, which may each be justifiable but
may have contrary effects on health care and health.
Implications for research
Research has been narrowly focused on assessing changes in screen-
ing test uptake after certain risk communication interventions.
The research needs to be broader, more consistently assessing af-
fective measures such as decisional conflict, satisfaction with deci-
sion or anxiety. There would also be value in developing a generic
measure of informed decision making for screening choices by
consumers. Using such a measure widely would also be important
in assessing the true effect of personalised risk communication on
people’s use of screening tests.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bastani 1999
Methods RCT
Participants Women over 30; breast cancer in first degree relative; resident in USA or Canada
Interventions Mailed personalised risk assessment notification and other theoretically driven
(Adherence Model) materials tailored for high risk women.
Outcomes Uptake of mammography one year after baseline survey.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Bowen 2002
Methods RCT
Participants Women with first degree relative with breast cancer; Seattle, USA
Interventions Individual or group-based genetic counselling, including Gail and Claus scores
Outcomes Interest in having BRCA tests; perception of self as appropriate candidate for tests
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Campbell 1997
Methods RCT
Participants Women who had not had a cervical (Pap) smear in previous 30 months; New South Wales,
Australia
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Campbell 1997 (Continued)
Interventions Computer generated printed feedback, listing ’risk factor’ of not having a smear within past
2 years
Outcomes Uptake of cervical (Pap) smear.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Champion 1994
Methods RCT
Participants Women aged >= 35 ; never having had breast cancer. USA.
Interventions In-home interviews conducted by graduate nursing research assistants. Discussion about
individual risk factors - susceptibility intervention- as part of a beliefmodifying intervention
Outcomes Change in beliefs and knowledge (including susceptibility scores) post-intervention; mam-
mography compliance 1 year post-intervention
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Champion 1995
Methods RCT
Participants Women aged >=35; not diagnosed with breast cancer.
USA. (Analysis of intervention effect only on those 40 years and over)
Interventions In-home interviews conducted by graduate nursing students.Discussion about individual
risk factors - susceptibility intervention - as part of a belief modifying intervention
Outcomes Change in beliefs and knowledge (including susceptibility (scores); mammography com-
pliance; movement across stages of change
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Champion 1995 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Champion 2000a
Methods RCT
Participants Low-income African American women aged 45-64; Indiana, USA.
Interventions In-person tailored interventions based on Health Belief and Transtheoretical Models, in-
cluding listing of susceptibility factors
Outcomes Screening mammography uptake at 12 months.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Champion 2002
Methods RCT
Participants Women aged over 50 not adherent to mammography recommendations; medical clinic at
St Louis and HMO in Indianapolis, USA
Interventions Tailored interventions based on Health Belief and Transtheoretical Models, including per-
ceived risk and risk factors (eg. age, family history)
Outcomes Self-reported mammography uptake at 2 months.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Champion 2003
Methods RCT
Participants Women in the 51-84 years age range who have not received a mammogram in the last 15
months; from an HMO and general medicine clinic, USA
Interventions Tailored interventions based onHealthBelief andTranstheoreticalModels, including listing
of susceptibility factors
Outcomes Screening mammography uptake at 6 months.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Curry 1993
Methods RCT
Participants Women aged >= 50; newly enrolled in an HMO, without prior history of breast cancer or
of mammography use in the previous 12 months. USA,
Interventions Mailed risk factor questionnaire plus personal risk invitation detailing personal risk factors
Outcomes Mammography use within 1 year of invitation.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Hutchison 1998
Methods RCT
Participants Patients aged 20-69 years, from 2 Canadian primary care group practices
Interventions Risk appraisal questionnaire (yielding risk score). Those with scores above 2 advised to go
for screening
Outcomes Rate of cholesterol testing during the three months of follow up
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Hutchison 1998 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Jibaja-Weiss 2003
Methods RCT
Participants Women registered at 2 urban community health centres; Houston, USA
Interventions Personalised letter, tailored for risk factor data and giving screening recommendations
Outcomes Scheduling and uptake of cervical (Pap) smear test and mammogram
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Low risk A - Adequate
Kreuter 1996
Methods RCT
Participants Patients aged 18-75 from 8 family medical practices, N. Carolina, USA
Interventions Mailed HRA (Health Risk Appraisal) - risk information tailored to information given at
baseline questionnaire
Outcomes Rate of pap smear, mammography and cholesterol uptake after 6 months in those contem-
plating these behaviours at baseline
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) High risk C - Inadequate
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Lee 1991
Methods RCT, stratified for previous screening history and risk status
Participants Federal employees aged >= 40 years. USA.
Interventions Colorectal cancer risk appraisal - categorised as high medium or low personal risk
Outcomes Knowledge, intention to take test, and uptake.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Lerman 1995
Methods RCT
Participants Women aged 35 years and older with a family history of breast cancer in a first degree
relative. USA
Interventions Breast cancer risk counselling including discussion of factors contributing to elevated risk
and presentation of individualized risk data
Outcomes Changes/improvement in risk comprehension.
Notes Additional paper (Lerman et al, 1996) addresses effects on general and breast cancer-specific
distress
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Lerman 1997
Methods RCT
Participants Women aged 18-75 who had at least one first degree relative with breast and/or ovarian
cancer. USA
Interventions Educational session including a review of individual risk factors for breast and ovarian
cancers
Outcomes Changes in risk perception; testing intentions.
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Lerman 1997 (Continued)
Notes No data on taking test in control group.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Lipkus 2005
Methods RCT (2 x 2 factorial with basic versus more comprehensive information as well as person-
alised (tailored) versus non-personalised
Participants 99% male, New Jersey Carpenters Fund members; aged over 50 years
Interventions Tailored risk information with information about risk factors for colorectal cancer derived
from baseline questionnaire
Outcomes Faecal Occult Blood test uptake at 1, 2 and 3 years.
Notes Also assessed ’attributions of colorectal cancer risk’ but not as risk perceptions directly
affected by interventions
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Myers 1999
Methods RCT
Participants African American men, aged 40-70 years. Patients at the University of Chicago, USA
Interventions A personalised ’ProRecord’ which included a tailored risk factors and symptoms form
Outcomes ’Adherence’, ie. men who made an office visit for prostate cancer education and early
detection within a year
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Myers 1999 (Continued)
Allocation concealment (selection bias) Unclear risk B - Unclear
Rimer 2002
Methods RCT
Participants Women in their 40s and 50s , and members of Blue Cross and Blue Shield, N. Carolina,
USA
Interventions Tailored print materials detailing a woman’s personal risk (numerical and graphical) of
breast cancer based on Gail score
Outcomes Knowledge, accuracy of risk perceptions; mammography uptake.
Notes Tailored print + telephone counselling arm excluded as different and extra content
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Saywell 1999
Methods RCT
Participants Women 50-85 years; non-compliant with mammography guidelines; no history of breast
cancer. USA,
Interventions Telephone and in-person counselling including discussion of personal risk factors
Outcomes Mammography compliance 4-6 weeks after counselling.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
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Schwartz 1999
Methods RCT
Participants Women with family history of breast cancer (first degree relative of sufferer) aged 40 years
and older. USA
Interventions Risk counselling including individualised risk figures.
Outcomes Self reported mammography use 1 year after (compared to baseline)
Notes This is a follow-up to the Lerman et al, 1995 trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Skinner 1994
Methods RCT, stratified between clinics.
Participants Female family practice attenders aged 40-65 years. USA.
Interventions Tailored text about beliefs, mammography stages, risk factors and barriers
Outcomes Mammography stage and uptake.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
Skinner 2002
Methods RCT
Participants Women with personal and family history of breast and/or ovarian cancer; N. Carolina,
USA
Interventions Tailored print materials about cancer, risk factors, genes and genetic testing and risk quartile
in verbal or verbal and numerical format according to woman’s preference
Outcomes Knowledge, anxiety, accuracy of perceived risk and intention to take genetic test
Notes
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Skinner 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment (selection bias) Unclear risk B - Unclear
RCT = randomised controlled trial.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alexander 1996 A one group pre-test and post-test design. No control group.
Champion 2000b Not personalised risk elements despite some attention to susceptibility; personalisation is for transtheoretical
stage
Dignan 1996 Individualised counselling based on each woman’s barriers to obtaining cervical screening, but not estimating
her personal level of risk or risk factors
Engelstad 2005 Intervention for follow-up of abnormal Pap smears, not screening
Gagnon 1996 Intervention involved counselling in which an estimate of a woman’s risk of developing breast cancer was given,
but no control group present; andmain behavioural outcome was not mammography but breast self-examination
Giles 2001 Personalised risks given, but no control group for this pre-post study
Kadison 1998 No control group.
Kreuter 2005 Tailoring for beliefs and cultural adaptation but not of risk information itself
Leigh 1991 A longitudinal study, with risk calculated after cardiovascular screening
Lipkus 2000 Tailored print and counselling, but no clear evidence that personalised risk information was given
Miller 2005 Patient initiated call for information, consideration of testing; not screening
Pye 1988 Identified from the Jepson review as being a ’risk factor assessment study’; but questionnaire assessed symptoms
and not risk factors as such
Rakowski 1998 Stage (of change) matched intervention but not explicitly dealing with individually calculated risk estimates
Rhodes 2001 Personal health recommendations but not risk communication in screening. Process measures and no outcomes
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(Continued)
Rimer 1999 A tailored intervention, but not with regards to personal risks
Weber 1997 Structured outreach, with identification and removal of barriers to care, but not estimating her personal level of
risk or risk factors
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D A T A A N D A N A L Y S E S
Comparison 1. personalised risk communication versus general risk information
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 knowledge regarding screening
test / condition concerned
2 568 Mean Difference (IV, Fixed, 95% CI) 2.45 [1.94, 2.96]
1.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
1 260 Mean Difference (IV, Fixed, 95% CI) 12.0 [6.89, 17.11]
1.3 personal risk factor list v
general information
1 308 Mean Difference (IV, Fixed, 95% CI) 2.35 [1.84, 2.86]
2 knowledge regarding screening
test / condition concerned
1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.95, 2.19]
2.1 calculated risk score
(numerical) v general
information
1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.95, 2.19]
2.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 perceived risk - perceiving self as
appropriate candidate for test
1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.35, 1.19]
3.1 calculated risk score
(numerical) v general
information
1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.35, 1.19]
3.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 accurately perceived risk 3 1264 Odds Ratio (M-H, Fixed, 95% CI) 1.46 [1.13, 1.88]
4.1 calculated risk score
(numerical) v general
information
2 1004 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [0.91, 1.64]
4.2 calculated risk score
(categorised) v general
information
1 260 Odds Ratio (M-H, Fixed, 95% CI) 2.50 [1.48, 4.20]
4.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 anxiety (Cancer related anxiety
and helplessness scale; IES
breast cancer distress)
2 499 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.30, 0.25]
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5.1 calculated risk score
(numerical) v general
information
1 239 Mean Difference (IV, Fixed, 95% CI) -4.1 [-7.54, -0.66]
5.2 calculated risk score
(categorised) v general
information
1 260 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.28, 0.28]
5.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 satisfaction with decision 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 decision conflict 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 intention to take screening test 5 2016 Odds Ratio (M-H, Fixed, 95% CI) 0.86 [0.71, 1.03]
8.1 calculated risk score
(numerical) v general
information
1 214 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.63, 1.94]
8.2 calculated risk score
(categorised) v general
information
2 538 Odds Ratio (M-H, Fixed, 95% CI) 1.68 [1.12, 2.53]
8.3 personal risk factor list v
general information
2 1264 Odds Ratio (M-H, Fixed, 95% CI) 0.68 [0.54, 0.84]
9 uptake of screening test 14 7341 Odds Ratio (M-H, Fixed, 95% CI) 1.13 [1.02, 1.24]
9.1 calculated risk score
(numerical) v general
information
2 1234 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.65, 1.03]
9.2 calculated risk score
(categorised) v general
information
2 1031 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [1.07, 1.89]
9.3 personal risk factor list v
general information
10 5076 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [1.04, 1.32]
10 appropriate use of cholesterol
test
1 3152 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [1.14, 1.55]
10.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 personal risk factor list v
general information
1 3152 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [1.14, 1.55]
11 smoking 1 204 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.60, 1.82]
11.1 calculated risk score
(numerical) v general
information
1 204 Odds Ratio (M-H, Fixed, 95% CI) 1.04 [0.60, 1.82]
11.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 stages of change Other data No numeric data
12.1 personal risk factor list v
general information
Other data No numeric data
13 improvement in risk
comprehension/perception
1 200 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.64 [0.83, 3.25]
13.1 calculated risk score
(numerical) v general
information
1 200 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.64 [0.83, 3.25]
13.2 calculated risk score
(categorised) v general
information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 personal risk factor list v
general information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 making a recommended
behaviour change
1 890 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.28]
14.1 personal risk factor list v
general information
1 890 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.76, 1.28]
14.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. personalised risk communication versus general risk information for PAP SMEARS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 intention to take screening test 1 984 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.74]
1.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.3 personal risk factor list v
general information
1 984 Odds Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.74]
2 uptake of screening test 3 1552 Odds Ratio (M-H, Fixed, 95% CI) 0.62 [0.50, 0.77]
2.1 calculated risk score
(numerical) v general
information
1 296 Odds Ratio (M-H, Fixed, 95% CI) 1.26 [0.75, 2.13]
2.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 personal risk factor list v
general information
2 1256 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.42, 0.67]
Comparison 3. personalised risk communication versus general risk information for MAMMOGRAPHY
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 knowledge regarding screening
test / condition concerned
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 knowledge regarding screening
test / condition concerned
1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.95, 2.19]
2.1 calculated risk score
(numerical) v general
information
1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.44 [0.95, 2.19]
2.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 accuracy of perceived risk 1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.86, 1.60]
3.1 calculated risk score
(numerical) v general
information
1 804 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.86, 1.60]
3.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 decision conflict 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 anxiety 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 satisfaction with decision 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 intention to take screening test 1 478 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.76]
7.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 personal risk factor list v
general information
1 478 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.36, 0.76]
8 uptake of screening test 11 5234 Odds Ratio (M-H, Fixed, 95% CI) 1.11 [0.98, 1.24]
8.1 calculated risk score
(numerical) v general
information
3 1456 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.66, 1.02]
8.2 calculated risk score
(categorised) v general
information
1 753 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [1.02, 1.84]
8.3 personal risk factor list v
general information
7 3025 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [1.04, 1.43]
9 stages of change Other data No numeric data
9.1 personal risk factor list v
general information
Other data No numeric data
10 anxiety (Cancer related anxiety
and helplessness scale)
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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10.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 improvement in risk
comprehension/perception
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.1 calculated risk score
(numerical) v general
information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 calculated risk score
(categorised) v general
information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.3 personal risk factor list v
general information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. personalised risk communication versus general risk information for CHOLESTEROL TESTS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 uptake of screening test 1 276 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.57, 1.65]
1.1 calculated risk score
(numerical) v general
information
1 276 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.57, 1.65]
1.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 appropriate use of cholesterol
test
1 3152 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [1.14, 1.55]
2.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 personal risk factor list v
general information
1 3152 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [1.14, 1.55]
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Comparison 5. personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 knowledge regarding screening
test / condition concerned
2 568 Mean Difference (IV, Fixed, 95% CI) 2.45 [1.94, 2.96]
1.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
1 260 Mean Difference (IV, Fixed, 95% CI) 12.0 [6.89, 17.11]
1.3 personal risk factor list v
general information
1 308 Mean Difference (IV, Fixed, 95% CI) 2.35 [1.84, 2.86]
2 perceived risk - perceiving self as
appropriate candidate for test
1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.35, 1.19]
2.1 calculated risk score
(numerical) v general
information
1 214 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.35, 1.19]
2.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 accurately perceived risk 2 460 Odds Ratio (M-H, Fixed, 95% CI) 2.25 [1.44, 3.53]
3.1 calculated risk score
(numerical) v general
information
1 200 Odds Ratio (M-H, Fixed, 95% CI) 1.69 [0.70, 4.06]
3.2 calculated risk score
(categorised) v general
information
1 260 Odds Ratio (M-H, Fixed, 95% CI) 2.50 [1.48, 4.20]
3.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 anxiety 2 499 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.30, 0.25]
4.1 calculated risk score
(numerical) v general
information
1 239 Mean Difference (IV, Fixed, 95% CI) -4.1 [-7.54, -0.66]
4.2 calculated risk score
(categorised) v general
information
1 260 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.28, 0.28]
4.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 satisfaction with decision 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 decision conflict 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 intention to take screening test 2 540 Odds Ratio (M-H, Fixed, 95% CI) 0.84 [0.55, 1.27]
7.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 calculated risk score
(categorised) v general
information
1 260 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.65]
7.3 personal risk factor list v
general information
1 280 Odds Ratio (M-H, Fixed, 95% CI) 1.17 [0.72, 1.89]
8 uptake of screening test 5 3145 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [1.23, 1.71]
8.1 calculated risk score
(numerical) v general
information
2 1355 Odds Ratio (M-H, Fixed, 95% CI) 1.48 [1.06, 2.07]
8.2 calculated risk score
(categorised) v general
information
1 753 Odds Ratio (M-H, Fixed, 95% CI) 1.37 [1.02, 1.84]
8.3 personal risk factor list v
general information
2 1037 Odds Ratio (M-H, Fixed, 95% CI) 1.49 [1.16, 1.91]
9 improvement in risk
comprehension/perception
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.1 calculated risk score
(numerical) v general
information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 calculated risk score
(categorised) v general
information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.3 personal risk factor list v
general information
0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 anxiety (Cancer related anxiety
and helplessness scale)
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.1 calculated risk score
(numerical) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 calculated risk score
(categorised) v general
information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.3 personal risk factor list v
general information
0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 6. personalised risk communication versus general risk information forCOLORECTALSCREENING
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 uptake of screening test 1 278 Odds Ratio (M-H, Fixed, 95% CI) 2.09 [0.76, 5.75]
1.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
1 278 Odds Ratio (M-H, Fixed, 95% CI) 2.09 [0.76, 5.75]
1.3 personal risk factor list v
general information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. personalised risk communication versus general risk information for PROSTATE CANCER
SCREENING
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 uptake of screening test 1 413 Odds Ratio (M-H, Fixed, 95% CI) 2.56 [1.70, 3.84]
1.1 calculated risk score
(numerical) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 calculated risk score
(categorised) v general
information
0 0 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 personal risk factor list v
general information
1 413 Odds Ratio (M-H, Fixed, 95% CI) 2.56 [1.70, 3.84]
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Analysis 1.1. Comparison 1 personalised risk communication versus general risk information, Outcome 1
knowledge regarding screening test / condition concerned.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 1 knowledge regarding screening test / condition concerned
Study or subgroup personalised risk general risk info Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Skinner 2002 130 78 (21) 130 66 (21) 1.0 % 12.00 [ 6.89, 17.11 ]
Subtotal (95% CI) 130 130 1.0 % 12.00 [ 6.89, 17.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
3 personal risk factor list v general information
Lerman 1997 128 7.74 (2.16) 180 5.39 (2.39) 99.0 % 2.35 [ 1.84, 2.86 ]
Subtotal (95% CI) 128 180 99.0 % 2.35 [ 1.84, 2.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.00 (P < 0.00001)
Total (95% CI) 258 310 100.0 % 2.45 [ 1.94, 2.96 ]
Heterogeneity: Chi2 = 13.59, df = 1 (P = 0.00023); I2 =93%
Test for overall effect: Z = 9.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.59, df = 1 (P = 0.00), I2 =93%
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Analysis 1.2. Comparison 1 personalised risk communication versus general risk information, Outcome 2
knowledge regarding screening test / condition concerned.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 2 knowledge regarding screening test / condition concerned
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Rimer 2002 59/392 45/412 100.0 % 1.44 [ 0.95, 2.19 ]
Subtotal (95% CI) 392 412 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 59 (personalised risk), 45 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 392 412 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 59 (personalised risk), 45 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 personalised risk communication versus general risk information, Outcome 3
perceived risk - perceiving self as appropriate candidate for test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 3 perceived risk - perceiving self as appropriate candidate for test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Bowen 2002 72/105 84/109 100.0 % 0.65 [ 0.35, 1.19 ]
Subtotal (95% CI) 105 109 100.0 % 0.65 [ 0.35, 1.19 ]
Total events: 72 (personalised risk), 84 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 105 109 100.0 % 0.65 [ 0.35, 1.19 ]
Total events: 72 (personalised risk), 84 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 personalised risk communication versus general risk information, Outcome 4
accurately perceived risk.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 4 accurately perceived risk
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Lerman 1995 13/90 10/110 7.9 % 1.69 [ 0.70, 4.06 ]
Rimer 2002 110/392 103/412 73.7 % 1.17 [ 0.86, 1.60 ]
Subtotal (95% CI) 482 522 81.6 % 1.22 [ 0.91, 1.64 ]
Total events: 123 (personalised risk), 113 (general risk info)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 calculated risk score (categorised) v general information
Skinner 2002 61/130 34/130 18.4 % 2.50 [ 1.48, 4.20 ]
Subtotal (95% CI) 130 130 18.4 % 2.50 [ 1.48, 4.20 ]
Total events: 61 (personalised risk), 34 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00058)
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 612 652 100.0 % 1.46 [ 1.13, 1.88 ]
Total events: 184 (personalised risk), 147 (general risk info)
Heterogeneity: Chi2 = 6.09, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Chi2 = 5.49, df = 1 (P = 0.02), I2 =82%
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Analysis 1.5. Comparison 1 personalised risk communication versus general risk information, Outcome 5
anxiety (Cancer related anxiety and helplessness scale; IES breast cancer distress).
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 5 anxiety (Cancer related anxiety and helplessness scale; IES breast cancer distress)
Study or subgroup personalised risk general risk info Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 calculated risk score (numerical) v general information
Lerman 1995 108 10.3 (12.7) 131 14.4 (14.4) 0.6 % -4.10 [ -7.54, -0.66 ]
Subtotal (95% CI) 108 131 0.6 % -4.10 [ -7.54, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
2 calculated risk score (categorised) v general information
Skinner 2002 130 -0.4 (1.14) 130 -0.4 (1.14) 99.4 % 0.0 [ -0.28, 0.28 ]
Subtotal (95% CI) 130 130 99.4 % 0.0 [ -0.28, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 238 261 100.0 % -0.03 [ -0.30, 0.25 ]
Heterogeneity: Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 5.43, df = 1 (P = 0.02), I2 =82%
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Analysis 1.8. Comparison 1 personalised risk communication versus general risk information, Outcome 8
intention to take screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 8 intention to take screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Bowen 2002 37/105 36/109 9.3 % 1.10 [ 0.63, 1.94 ]
Subtotal (95% CI) 105 109 9.3 % 1.10 [ 0.63, 1.94 ]
Total events: 37 (personalised risk), 36 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
2 calculated risk score (categorised) v general information
Lee 1991 87/139 50/139 7.6 % 2.98 [ 1.83, 4.85 ]
Skinner 2002 113/130 126/130 6.7 % 0.21 [ 0.07, 0.65 ]
Subtotal (95% CI) 269 269 14.3 % 1.68 [ 1.12, 2.53 ]
Total events: 200 (personalised risk), 176 (general risk info)
Heterogeneity: Chi2 = 18.50, df = 1 (P = 0.00002); I2 =95%
Test for overall effect: Z = 2.50 (P = 0.013)
3 personal risk factor list v general information
Jibaja-Weiss 2003 208/524 245/460 63.8 % 0.58 [ 0.45, 0.74 ]
Lerman 1997 66/116 87/164 12.6 % 1.17 [ 0.72, 1.89 ]
Subtotal (95% CI) 640 624 76.4 % 0.68 [ 0.54, 0.84 ]
Total events: 274 (personalised risk), 332 (general risk info)
Heterogeneity: Chi2 = 6.50, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 3.46 (P = 0.00054)
Total (95% CI) 1014 1002 100.0 % 0.86 [ 0.71, 1.03 ]
Total events: 511 (personalised risk), 544 (general risk info)
Heterogeneity: Chi2 = 42.77, df = 4 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.63 (P = 0.10)
Test for subgroup differences: Chi2 = 15.67, df = 2 (P = 0.00), I2 =87%
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Analysis 1.9. Comparison 1 personalised risk communication versus general risk information, Outcome 9
uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 9 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Rimer 2002 204/392 231/412 14.2 % 0.85 [ 0.64, 1.12 ]
Schwartz 1999 148/215 161/215 6.6 % 0.74 [ 0.49, 1.13 ]
Subtotal (95% CI) 607 627 20.8 % 0.82 [ 0.65, 1.03 ]
Total events: 352 (personalised risk), 392 (general risk info)
Heterogeneity: Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
2 calculated risk score (categorised) v general information
Bastani 1999 249/382 214/371 9.9 % 1.37 [ 1.02, 1.84 ]
Lee 1991 12/139 6/139 0.7 % 2.09 [ 0.76, 5.75 ]
Subtotal (95% CI) 521 510 10.7 % 1.42 [ 1.07, 1.89 ]
Total events: 261 (personalised risk), 220 (general risk info)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
3 personal risk factor list v general information
Campbell 1997 52/148 33/124 3.1 % 1.49 [ 0.89, 2.52 ]
Champion 1994 117/147 103/153 2.7 % 1.89 [ 1.12, 3.20 ]
Champion 1995 146/191 142/214 4.1 % 1.65 [ 1.06, 2.55 ]
Champion 2000a 105/139 99/139 3.2 % 1.25 [ 0.73, 2.13 ]
Champion 2003 111/242 34/134 3.1 % 2.49 [ 1.57, 3.96 ]
Curry 1993 162/413 161/428 12.6 % 1.07 [ 0.81, 1.41 ]
Jibaja-Weiss 2003 124/524 202/460 21.6 % 0.40 [ 0.30, 0.52 ]
Myers 1999 98/192 64/221 3.8 % 2.56 [ 1.70, 3.84 ]
Saywell 1999 69/237 20/110 2.5 % 1.85 [ 1.06, 3.23 ]
Lipkus 2005 270/432 238/428 11.8 % 1.33 [ 1.01, 1.75 ]
Subtotal (95% CI) 2665 2411 68.6 % 1.17 [ 1.04, 1.32 ]
Total events: 1254 (personalised risk), 1096 (general risk info)
Heterogeneity: Chi2 = 95.28, df = 9 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.69 (P = 0.0072)
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(. . . Continued)
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 3793 3548 100.0 % 1.13 [ 1.02, 1.24 ]
Total events: 1867 (personalised risk), 1708 (general risk info)
Heterogeneity: Chi2 = 106.70, df = 13 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 10.55, df = 2 (P = 0.01), I2 =81%
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Analysis 1.10. Comparison 1 personalised risk communication versus general risk information, Outcome 10
appropriate use of cholesterol test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 10 appropriate use of cholesterol test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Hutchison 1998 1143/1549 1090/1603 100.0 % 1.32 [ 1.14, 1.55 ]
Subtotal (95% CI) 1549 1603 100.0 % 1.32 [ 1.14, 1.55 ]
Total events: 1143 (personalised risk), 1090 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
Total (95% CI) 1549 1603 100.0 % 1.32 [ 1.14, 1.55 ]
Total events: 1143 (personalised risk), 1090 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 personalised risk communication versus general risk information, Outcome 11
smoking.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 11 smoking
Study or subgroup personalised risk prior levels Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Kreuter 1996 61/102 60/102 100.0 % 1.04 [ 0.60, 1.82 ]
Subtotal (95% CI) 102 102 100.0 % 1.04 [ 0.60, 1.82 ]
Total events: 61 (personalised risk), 60 (prior levels)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (prior levels)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (prior levels)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 102 102 100.0 % 1.04 [ 0.60, 1.82 ]
Total events: 61 (personalised risk), 60 (prior levels)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 personalised risk communication versus general risk information, Outcome 12
stages of change.
stages of change
Study
personal risk factor list v general information
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stages of change (Continued)
Skinner 1994 71% did not change; 14% advanced one stage; 12% ’regressed’: no significant differences between tailored message
and control
Analysis 1.13. Comparison 1 personalised risk communication versus general risk information, Outcome 13
improvement in risk comprehension/perception.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 13 improvement in risk comprehension/perception
Study or subgroup personal risk info general risk info Peto Odds Ratio Weight Peto Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 calculated risk score (numerical) v general information
Lerman 1995 23/90 19/110 100.0 % 1.64 [ 0.83, 3.25 ]
Subtotal (95% CI) 90 110 100.0 % 1.64 [ 0.83, 3.25 ]
Total events: 23 (personal risk info), 19 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
2 calculated risk score(categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personal risk info), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personal risk info), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 90 110 100.0 % 1.64 [ 0.83, 3.25 ]
Total events: 23 (personal risk info), 19 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 personalised risk communication versus general risk information, Outcome 14
making a recommended behaviour change.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 1 personalised risk communication versus general risk information
Outcome: 14 making a recommended behaviour change
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 personal risk factor list v general information
Kreuter 1996 227/427 248/463 100.0 % 0.98 [ 0.76, 1.28 ]
Subtotal (95% CI) 427 463 100.0 % 0.98 [ 0.76, 1.28 ]
Total events: 227 (personalised risk), 248 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 calculated risk score(categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 427 463 100.0 % 0.98 [ 0.76, 1.28 ]
Total events: 227 (personalised risk), 248 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 personalised risk communication versus general risk information for PAP
SMEARS, Outcome 1 intention to take screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 2 personalised risk communication versus general risk information for PAP SMEARS
Outcome: 1 intention to take screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Jibaja-Weiss 2003 208/524 245/460 100.0 % 0.58 [ 0.45, 0.74 ]
Subtotal (95% CI) 524 460 100.0 % 0.58 [ 0.45, 0.74 ]
Total events: 208 (personalised risk), 245 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000022)
Total (95% CI) 524 460 100.0 % 0.58 [ 0.45, 0.74 ]
Total events: 208 (personalised risk), 245 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000022)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 personalised risk communication versus general risk information for PAP
SMEARS, Outcome 2 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 2 personalised risk communication versus general risk information for PAP SMEARS
Outcome: 2 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Kreuter 1996 46/162 32/134 11.8 % 1.26 [ 0.75, 2.13 ]
Subtotal (95% CI) 162 134 11.8 % 1.26 [ 0.75, 2.13 ]
Total events: 46 (personalised risk), 32 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Campbell 1997 52/148 33/124 11.0 % 1.49 [ 0.89, 2.52 ]
Jibaja-Weiss 2003 124/524 202/460 77.2 % 0.40 [ 0.30, 0.52 ]
Subtotal (95% CI) 672 584 88.2 % 0.53 [ 0.42, 0.67 ]
Total events: 176 (personalised risk), 235 (general risk info)
Heterogeneity: Chi2 = 19.52, df = 1 (P<0.00001); I2 =95%
Test for overall effect: Z = 5.22 (P < 0.00001)
Total (95% CI) 834 718 100.0 % 0.62 [ 0.50, 0.77 ]
Total events: 222 (personalised risk), 267 (general risk info)
Heterogeneity: Chi2 = 28.37, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 4.40 (P = 0.000011)
Test for subgroup differences: Chi2 = 8.69, df = 1 (P = 0.00), I2 =88%
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Analysis 3.2. Comparison 3 personalised risk communication versus general risk information for
MAMMOGRAPHY, Outcome 2 knowledge regarding screening test / condition concerned.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 3 personalised risk communication versus general risk information for MAMMOGRAPHY
Outcome: 2 knowledge regarding screening test / condition concerned
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Rimer 2002 59/392 45/412 100.0 % 1.44 [ 0.95, 2.19 ]
Subtotal (95% CI) 392 412 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 59 (personalised risk), 45 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 392 412 100.0 % 1.44 [ 0.95, 2.19 ]
Total events: 59 (personalised risk), 45 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 personalised risk communication versus general risk information for
MAMMOGRAPHY, Outcome 3 accuracy of perceived risk.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 3 personalised risk communication versus general risk information for MAMMOGRAPHY
Outcome: 3 accuracy of perceived risk
Study or subgroup persoanlised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Rimer 2002 110/392 103/412 100.0 % 1.17 [ 0.86, 1.60 ]
Subtotal (95% CI) 392 412 100.0 % 1.17 [ 0.86, 1.60 ]
Total events: 110 (persoanlised risk), 103 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (persoanlised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (persoanlised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 392 412 100.0 % 1.17 [ 0.86, 1.60 ]
Total events: 110 (persoanlised risk), 103 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 personalised risk communication versus general risk information for
MAMMOGRAPHY, Outcome 7 intention to take screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 3 personalised risk communication versus general risk information for MAMMOGRAPHY
Outcome: 7 intention to take screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Jibaja-Weiss 2003 120/239 157/239 100.0 % 0.53 [ 0.36, 0.76 ]
Subtotal (95% CI) 239 239 100.0 % 0.53 [ 0.36, 0.76 ]
Total events: 120 (personalised risk), 157 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00064)
Total (95% CI) 239 239 100.0 % 0.53 [ 0.36, 0.76 ]
Total events: 120 (personalised risk), 157 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.41 (P = 0.00064)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 personalised risk communication versus general risk information for
MAMMOGRAPHY, Outcome 8 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 3 personalised risk communication versus general risk information for MAMMOGRAPHY
Outcome: 8 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Kreuter 1996 33/120 31/102 4.5 % 0.87 [ 0.49, 1.55 ]
Rimer 2002 204/392 231/412 20.1 % 0.85 [ 0.64, 1.12 ]
Schwartz 1999 148/215 161/215 9.3 % 0.74 [ 0.49, 1.13 ]
Subtotal (95% CI) 727 729 34.0 % 0.82 [ 0.66, 1.02 ]
Total events: 385 (personalised risk), 423 (general risk info)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.076)
2 calculated risk score (categorised) v general information
Bastani 1999 249/382 214/371 14.1 % 1.37 [ 1.02, 1.84 ]
Subtotal (95% CI) 382 371 14.1 % 1.37 [ 1.02, 1.84 ]
Total events: 249 (personalised risk), 214 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
3 personal risk factor list v general information
Champion 1994 117/147 103/153 3.8 % 1.89 [ 1.12, 3.20 ]
Champion 1995 146/191 142/214 5.9 % 1.65 [ 1.06, 2.55 ]
Champion 2000a 105/139 99/139 4.5 % 1.25 [ 0.73, 2.13 ]
Champion 2003 111/242 34/134 4.4 % 2.49 [ 1.57, 3.96 ]
Curry 1993 162/413 161/428 17.9 % 1.07 [ 0.81, 1.41 ]
Jibaja-Weiss 2003 31/239 73/239 11.8 % 0.34 [ 0.21, 0.54 ]
Saywell 1999 69/237 20/110 3.6 % 1.85 [ 1.06, 3.23 ]
Subtotal (95% CI) 1608 1417 52.0 % 1.22 [ 1.04, 1.43 ]
Total events: 741 (personalised risk), 632 (general risk info)
Heterogeneity: Chi2 = 45.45, df = 6 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.46 (P = 0.014)
Total (95% CI) 2717 2517 100.0 % 1.11 [ 0.98, 1.24 ]
Total events: 1375 (personalised risk), 1269 (general risk info)
Heterogeneity: Chi2 = 56.72, df = 10 (P<0.00001); I2 =82%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Chi2 = 10.80, df = 2 (P = 0.00), I2 =81%
0.1 0.2 0.5 1 2 5 10
favours general favours personal
54Personalised risk communication for informed decision making about taking screening tests (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.9. Comparison 3 personalised risk communication versus general risk information for
MAMMOGRAPHY, Outcome 9 stages of change.
stages of change
Study
personal risk factor list v general information
Skinner 1994 71% did not change; 14% advanced one stage; 12% ’regressed’: no significant differences between tailored message
and control
Analysis 4.1. Comparison 4 personalised risk communication versus general risk information for
CHOLESTEROL TESTS, Outcome 1 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 4 personalised risk communication versus general risk information for CHOLESTEROL TESTS
Outcome: 1 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Kreuter 1996 36/132 40/144 100.0 % 0.98 [ 0.57, 1.65 ]
Subtotal (95% CI) 132 144 100.0 % 0.98 [ 0.57, 1.65 ]
Total events: 36 (personalised risk), 40 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 132 144 100.0 % 0.98 [ 0.57, 1.65 ]
Total events: 36 (personalised risk), 40 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 personalised risk communication versus general risk information for
CHOLESTEROL TESTS, Outcome 2 appropriate use of cholesterol test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 4 personalised risk communication versus general risk information for CHOLESTEROL TESTS
Outcome: 2 appropriate use of cholesterol test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Hutchison 1998 1143/1549 1090/1603 100.0 % 1.32 [ 1.14, 1.55 ]
Subtotal (95% CI) 1549 1603 100.0 % 1.32 [ 1.14, 1.55 ]
Total events: 1143 (personalised risk), 1090 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
Total (95% CI) 1549 1603 100.0 % 1.32 [ 1.14, 1.55 ]
Total events: 1143 (personalised risk), 1090 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 1 knowledge regarding screening test / condition concerned.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 1 knowledge regarding screening test / condition concerned
Study or subgroup personalised risk general risk info Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Skinner 2002 130 78 (21) 130 66 (21) 1.0 % 12.00 [ 6.89, 17.11 ]
Subtotal (95% CI) 130 130 1.0 % 12.00 [ 6.89, 17.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
3 personal risk factor list v general information
Lerman 1997 128 7.74 (2.16) 180 5.39 (2.39) 99.0 % 2.35 [ 1.84, 2.86 ]
Subtotal (95% CI) 128 180 99.0 % 2.35 [ 1.84, 2.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 9.00 (P < 0.00001)
Total (95% CI) 258 310 100.0 % 2.45 [ 1.94, 2.96 ]
Heterogeneity: Chi2 = 13.59, df = 1 (P = 0.00023); I2 =93%
Test for overall effect: Z = 9.41 (P < 0.00001)
Test for subgroup differences: Chi2 = 13.59, df = 1 (P = 0.00), I2 =93%
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Analysis 5.2. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 2 perceived risk - perceiving self as appropriate candidate for test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 2 perceived risk - perceiving self as appropriate candidate for test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Bowen 2002 72/105 84/109 100.0 % 0.65 [ 0.35, 1.19 ]
Subtotal (95% CI) 105 109 100.0 % 0.65 [ 0.35, 1.19 ]
Total events: 72 (personalised risk), 84 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 105 109 100.0 % 0.65 [ 0.35, 1.19 ]
Total events: 72 (personalised risk), 84 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours personal Favours general
58Personalised risk communication for informed decision making about taking screening tests (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.3. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 3 accurately perceived risk.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 3 accurately perceived risk
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Lerman 1995 13/90 10/110 29.9 % 1.69 [ 0.70, 4.06 ]
Subtotal (95% CI) 90 110 29.9 % 1.69 [ 0.70, 4.06 ]
Total events: 13 (personalised risk), 10 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 calculated risk score (categorised) v general information
Skinner 2002 61/130 34/130 70.1 % 2.50 [ 1.48, 4.20 ]
Subtotal (95% CI) 130 130 70.1 % 2.50 [ 1.48, 4.20 ]
Total events: 61 (personalised risk), 34 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 3.44 (P = 0.00058)
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 220 240 100.0 % 2.25 [ 1.44, 3.53 ]
Total events: 74 (personalised risk), 44 (general risk info)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.56 (P = 0.00036)
Test for subgroup differences: Chi2 = 0.56, df = 1 (P = 0.45), I2 =0.0%
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Analysis 5.4. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 4 anxiety.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 4 anxiety
Study or subgroup personalised risk general risk info Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 calculated risk score (numerical) v general information
Lerman 1995 108 10.3 (12.7) 131 14.4 (14.4) 0.6 % -4.10 [ -7.54, -0.66 ]
Subtotal (95% CI) 108 131 0.6 % -4.10 [ -7.54, -0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
2 calculated risk score (categorised) v general information
Skinner 2002 130 -0.4 (1.14) 130 -0.4 (1.14) 99.4 % 0.0 [ -0.28, 0.28 ]
Subtotal (95% CI) 130 130 99.4 % 0.0 [ -0.28, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 238 261 100.0 % -0.03 [ -0.30, 0.25 ]
Heterogeneity: Chi2 = 5.43, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Chi2 = 5.43, df = 1 (P = 0.02), I2 =82%
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Analysis 5.7. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 7 intention to take screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 7 intention to take screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Skinner 2002 113/130 126/130 34.7 % 0.21 [ 0.07, 0.65 ]
Subtotal (95% CI) 130 130 34.7 % 0.21 [ 0.07, 0.65 ]
Total events: 113 (personalised risk), 126 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0064)
3 personal risk factor list v general information
Lerman 1997 66/116 87/164 65.3 % 1.17 [ 0.72, 1.89 ]
Subtotal (95% CI) 116 164 65.3 % 1.17 [ 0.72, 1.89 ]
Total events: 66 (personalised risk), 87 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 246 294 100.0 % 0.84 [ 0.55, 1.27 ]
Total events: 179 (personalised risk), 213 (general risk info)
Heterogeneity: Chi2 = 7.70, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Chi2 = 7.60, df = 1 (P = 0.01), I2 =87%
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Analysis 5.8. Comparison 5 personalised risk communication versus general risk information for ’HIGH
RISK’ PEOPLE, Outcome 8 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 5 personalised risk communication versus general risk information for ’HIGH RISK’ PEOPLE
Outcome: 8 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Hutchison 1998 45/421 9/504 3.1 % 6.58 [ 3.18, 13.63 ]
Schwartz 1999 148/215 161/215 21.3 % 0.74 [ 0.49, 1.13 ]
Subtotal (95% CI) 636 719 24.4 % 1.48 [ 1.06, 2.07 ]
Total events: 193 (personalised risk), 170 (general risk info)
Heterogeneity: Chi2 = 26.48, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 2.32 (P = 0.020)
2 calculated risk score (categorised) v general information
Bastani 1999 249/382 214/371 32.1 % 1.37 [ 1.02, 1.84 ]
Subtotal (95% CI) 382 371 32.1 % 1.37 [ 1.02, 1.84 ]
Total events: 249 (personalised risk), 214 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
3 personal risk factor list v general information
Curry 1993 50/75 44/102 5.3 % 2.64 [ 1.42, 4.90 ]
Lipkus 2005 270/432 238/428 38.1 % 1.33 [ 1.01, 1.75 ]
Subtotal (95% CI) 507 530 43.4 % 1.49 [ 1.16, 1.91 ]
Total events: 320 (personalised risk), 282 (general risk info)
Heterogeneity: Chi2 = 3.92, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 3.14 (P = 0.0017)
Total (95% CI) 1525 1620 100.0 % 1.45 [ 1.23, 1.71 ]
Total events: 762 (personalised risk), 666 (general risk info)
Heterogeneity: Chi2 = 30.39, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.19, df = 2 (P = 0.91), I2 =0.0%
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Analysis 6.1. Comparison 6 personalised risk communication versus general risk information for
COLORECTAL SCREENING, Outcome 1 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 6 personalised risk communication versus general risk information for COLORECTAL SCREENING
Outcome: 1 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Lee 1991 12/139 6/139 100.0 % 2.09 [ 0.76, 5.75 ]
Subtotal (95% CI) 139 139 100.0 % 2.09 [ 0.76, 5.75 ]
Total events: 12 (personalised risk), 6 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
3 personal risk factor list v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 139 139 100.0 % 2.09 [ 0.76, 5.75 ]
Total events: 12 (personalised risk), 6 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
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Analysis 7.1. Comparison 7 personalised risk communication versus general risk information for
PROSTATE CANCER SCREENING, Outcome 1 uptake of screening test.
Review: Personalised risk communication for informed decision making about taking screening tests
Comparison: 7 personalised risk communication versus general risk information for PROSTATE CANCER SCREENING
Outcome: 1 uptake of screening test
Study or subgroup personalised risk general risk info Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 calculated risk score (numerical) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 calculated risk score (categorised) v general information
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (personalised risk), 0 (general risk info)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 personal risk factor list v general information
Myers 1999 98/192 64/221 100.0 % 2.56 [ 1.70, 3.84 ]
Subtotal (95% CI) 192 221 100.0 % 2.56 [ 1.70, 3.84 ]
Total events: 98 (personalised risk), 64 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 4.54 (P < 0.00001)
Total (95% CI) 192 221 100.0 % 2.56 [ 1.70, 3.84 ]
Total events: 98 (personalised risk), 64 (general risk info)
Heterogeneity: not applicable
Test for overall effect: Z = 4.54 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
favours general favours personal
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A P P E N D I C E S
Appendix 1. Search Strategy: CENTRAL
The Cochrane Central Register of Controlled Trials (CENTRAL (The Cochrane Library Issue 4, 2004))
1. risk* or (patient near tailor*) or (patient near personal*) or (patients near tailor*) or (patients near personal*) or (consumer* near
tailor*) or (consumer* near personal*) or (recipient* near tailor*) or (recipient* near personal*) or (tailor* near message*) or (individual*
near message*) or (personal* near message*)
2. RISK explode all trees (MeSH)
3. (#1 or #2)
4. COMMUNICATION single term (MeSH)
5. PERSUASIVE COMMUNICATION single term (MeSH)
6. COUNSELING single term (MeSH)
7. GENETIC COUNSELING single term (MeSH)
8. HEALTH PROMOTION single term (MeSH)
9. PATIENT EDUCATION single term (MeSH)
10. HEALTH KNOWLEDGE ATTITUDES PRACTICE single term (MeSH)
11. PATIENT ACCEPTANCE OF HEALTH CARE single term (MeSH)
12. ATTITUDE TO HEALTH single term (MeSH)
13. DECISION MAKING single term (MeSH)
14. CHOICE BEHAVIOR single term (MeSH)
15. INFORMED CONSENT single term (MeSH)
16. ((patient near communicat*) or (patient near educat*) or (patient near counsel*) or (patient near inform*) or (patient near discuss*)
or (patient near decision*) or (patient near decide*) or (patient near participat*) or (patient near attitude*) or (patient near accept*) or
(patient near choice*))
17. ((patients near communicat*) or (patients near educat*) or (patients near counsel*) or (patients near inform*) or (patients near
discuss*) or (patients near decision*) or (patients near decide*) or (patients near participat*) or (patients near attitude*) or (patients
near accept*) or (patients near choice*))
18. ((consumer* near communicat*) or (consumer* near educat*) or (consumer* near counsel*) or (consumer* near inform*) or
(consumer* near discuss*) or (consumer* near decision*) or (consumer* near decide*) or (consumer* near participat*) or (consumer*
near attitude*) or (consumer* near accept*) or (consumer* near choice*))
19. (#4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18)
20. (#3 and #19)
21. MASS SCREENING explode all trees (MeSH)
22. MAMMOGRAPHY single term (MeSH)
23. VAGINAL SMEARS single term (MeSH)
24. OCCULT BLOOD single term (MeSH)
25. PROSTATE-SPECIFIC ANTIGEN single term (MeSH)
26. COLONOSCOPY explode all trees (MeSH)
27. PRECANCEROUS CONDITIONS single term (MeSH)
28. CERVIX DYSPLASIA single term (MeSH)
29. EARLY DIAGNOSIS single term (MeSH)
30. (screen* or mammography or mammogram* or (vaginal next smear) or (occult next blood) or (prostate next specific next antigen)
or colonoscopy or sigmoidoscopy)
31. neoplasm*
32. (brca1 or brca2)
33. (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32)
34. (#20 and #33)
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Appendix 2. Search Strategy: CINAHL
CINAHL (Ovid) (1985 to December 2005)
1. risk$.mp.
2. ((patient$ or consumer$ or recipient$) adj5 (tailor$ or personal$)).tw.
3. ((tailor$ or individual$ or personal$) adj5 message$).tw.
4. or/1-3
5. Communication/
6. “GENETIC COUNSELING (IOWA NIC)”/ or “COUNSELING (IOWA NIC)”/ or COUNSELING/ or “HEALTH TEACH-
ING, GUIDANCE AND COUNSELING (OMAHA)”/ or GENETIC COUNSELING/
7. Patient Education/
8. Health Education/
9. Health Promotion/
10. Health Knowledge/
11. ((patient$ or consumer$) adj3 (communicat$ or counsel$ or inform$ or discuss$ or decision$ or decide$ or participat$)).tw.
12. attitude to health/ or patient attitudes/
13. Health Beliefs/
14. Health Behavior/
15. decision making/ or decision making, patient/
16. informed consent/
17. or/5-16
18. health screening/ or cancer screening/ or genetic screening/
19. Cervical Smears/
20. mammography/
21. Occult Blood/
22. tumor markers, biological/ or prostate-specific antigen/
23. colonoscopy/ or sigmoidoscopy/
24. Precancerous Conditions/
25. screen$.tw.
26. neoplasms.mp.
27. (BRCA1 or BRCA2).tw.
28. or/18-27
29. randomi?ed controlled trial$.af.
30. random$.tw.
31. clinical trial.pt.
32. exp clinical trials/
33. (clin$ adj25 trial$).tw.
34. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
35. placebos/
36. placebo$.tw.
37. exp study design/
38. or/29-37
39. 4 and 17 and 28 and 38
40. limit 39 to yr=1985-2005
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Appendix 3. Search Strategy: EMBASE
EMBASE (Ovid) (1985 to December 2005)
1. risk/ or cardiovascular risk/ or genetic risk/ or high risk patient/ or high risk population/ or population risk/ or risk assessment/ or
risk benefit analysis/ or risk factor/ or risk management/
2. cancer risk/ or fetus risk/
3. risk$.tw.
4. ((patient$ or consumer$ or recipient$) adj5 (tailor$ or personal$)).tw.
5. ((tailor$ or individual$ or personal$) adj5 message$).tw.
6. or/1-5
7. interpersonal communication/ or persuasive communication/ or verbal communication/
8. counseling/ or genetic counseling/ or parent counseling/ or patient counseling/
9. health education/ or health promotion/ or patient education/
10. attitude/
11. decision making/
12. informed consent/
13. ((patient$ or consumer$) adj3 (communicat$ or counsel$ or inform$ or discuss$ or decision$ or decide$ or participat$)).tw.
14. or/7-13
15. screening/ or screening test/ or mass screening/ or cancer screening/ or genetic screening/ or newborn screening/ or prenatal
screening/
16. mammography/
17. vagina smear/
18. occult blood/
19. Prostate Specific Antigen/
20. colonoscopy/ or sigmoidoscopy/
21. Precancer/
22. early diagnosis/
23. screen$.tw.
24. neoplasms.mp.
25. (BRCA1 or BRCA2).tw.
26. or/15-25
27. 6 and 14 and 26
28. randomized controlled trial/
29. random$.tw.
30. exp controlled study/
31. double blind procedure/
32. single blind procedure/
33. crossover procedure/
34. latin square design/
35. multicenter study/
36. ((clinical or controlled or comparative or placebo or prospective or random$) adj3 (trial or study)).tw.
37. ((single$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).tw.
38. (crossover$ or cross-over$ or (cross adj1 over$)).tw.
39. ((allocat$ or allot$ or assign$ or divid$) adj3 (condition$ or experiment$ or intervention$ or treatment$ or therap$ or control$ or
group$)).tw.
40. or/28-39
41. exp animal/ or nonhuman/
42. human/
43. 41 and 42
44. 41 not 43
45. 40 not 44
46. 27 and 45
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47. limit 46 to yr=1985-2005
Appendix 4. Search Strategy: MEDLINE
MEDLINE (Ovid) (1985 to December 2005)
1. exp risk/
2. risk$.tw.
3. ((patient$ or consumer$ or recipient$) adj5 (tailor$ or personal$)).tw.
4. ((tailor$ or individual$ or personal$) adj5 message$).tw.
5. or/1-4
6. communication/
7. persuasive communication/
8. counseling/
9. genetic counseling/
10. health promotion/
11. Patient Education/
12. health knowledge, attitudes, practice/
13. ((patient$ or consumer$) adj3 (communicat$ or counsel$ or inform$ or discuss$ or decision$ or decide$ or participat$)).tw.
14. “Patient Acceptance of Health Care”/
15. Attitude to Health/
16. decision making/ or choice behavior/
17. Informed Consent/
18. or/6-17
19. exp mass screening/
20. Mammography/
21. Vaginal Smears/
22. occult blood/
23. Prostate-Specific Antigen/
24. colonoscopy/ or sigmoidoscopy/
25. precancerous conditions/ or cervix dysplasia/
26. early diagnosis/
27. screen$.tw.
28. neoplasms.mp.
29. (BRCA1 or BRCA2).tw.
30. or/19-29
31. 5 and 18 and 30
32. clinical trial.pt.
33. random$.af.
34. placebo$.af.
35. ((singl$ or doubl$) adj25 (blind$ or mask$)).af.
36. or/32-35
37. animals/
38. human/
39. 37 and 38
40. 37 not 39
41. 36 not 40
42. 31 and 41
43. limit 42 to yr=1985-2005
68Personalised risk communication for informed decision making about taking screening tests (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 5. Search Strategy: PsycINFO
PsycINFO (Ovid) (1985 to December 2005)
1. exp RISK PERCEPTION/ or exp RISK ANALYSIS/ or exp RISK FACTORS/ or exp RISK TAKING/
2. risk$.mp.
3. ((patient$ or consumer$ or recipient$) adj5 (tailor$ or personal$)).tw.
4. ((tailor$ or individual$ or personal$) adj5 message$).tw.
5. or/1-4
6. interpersonal communication/ or communication/
7. persuasive communication/
8. counseling/ or genetic counseling/
9. health education/ or client education/ or health promotion/
10. health attitudes/ or health knowledge/ or health behavior/
11. decision making/ or choice behavior/
12. informed consent/
13. ((patient$ or consumer$) adj3 (communicat$ or counsel$ or inform$ or discuss$ or decision$ or decide$ or participat$)).tw.
14. or/6-13
15. screening tests/ or cancer screening/ or health screening/ or screening/
16. mammography/
17. screen$.tw.
18. (neoplasm$ or cancer$).tw.
19. or/15-18
20. 5 and 14 and 19
21. randomi?ed controlled trial$.af.
22. random$.tw.
23. (clin$ adj25 trial$).tw.
24. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
25. placebo/
26. placebo$.tw.
27. (cross over or crossover).tw.
28. latin square.tw.
29. exp treatment effectiveness evaluation/
30. exp mental health program evaluation/
31. exp experimental design/
32. or/21-31
33. animal.po.
34. (human or inpatient or outpatient).po.
35. 33 and 34
36. 33 not 35
37. 32 not 36
38. 20 and 37
39. limit 38 to yr=1985-2005
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F E E D B A C K
Comment from Jeppe Schroll, 30 September 2011
Summary
In the first comparison 1.1.1 the authors include two studies
Personalised risk:
1) Skinner: Mean (SD): 78 (21)
2) Kerman: Mean (SD): 7.74 (2.16)
Combining these results with mean difference results in extreme heterogeneity.
When analysing the large difference in mean and standard deviation (SD) it seems these studies might be using different scales, and a
standardized mean difference
might be the right choice for this analysis.
We discuss your specific Cochrane review in a published paper about heterogeneity: http://www.biomedcentral.com/1471-2288/11/
22
Regards
Jeppe Schroll
Reply
We thank Dr. Schroll for his comment. We are updating the review at present and will investigate his feedback in detail during the
update process.
Contributors
Adrian Edwards, 8 November 2011
WH A T ’ S N E W
Last assessed as up-to-date: 30 December 2005.
Date Event Description
8 November 2011 Feedback has been incorporated Feedback from Jeppe Schroll was received in September 2011 (see Feedback
1).The review authors are updating their review (as at November 2011) and
will investigate his feedback in detail during the update process
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H I S T O R Y
Protocol first published: Issue 4, 1999
Review first published: Issue 1, 2003
Date Event Description
18 April 2008 Amended Converted to new review format.
21 July 2006 New citation required and conclusions have changed Substantive amendment.
The review was updated on Issue 4 2006 of The Cochrane
Library.Nine new studies were identified, bringing the total
number of included studies to 22. The review’s conclusions
were amended in light of the new studies included in the
review.
The title of the review also changed slightly. It was first pub-
lished on Issue 1 2003 of The Cochrane Library as “Person-
alised risk communication for informed decision making
about entering screening programs”
C O N T R I B U T I O N S O F A U T H O R S
AE developed the protocol for the review, with input fromGE; JD conducted the literature searches; AE and one of JD or SH appraised
all studies for inclusion of exclusion and for data extraction; KH gave statistical advice regarding data extraction and synthesis; all
authors contributed to discussions and drafting of the review report. AE is the guarantor for the review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Department of Health, UK.
• Cochrane Health Promotion and Public Health Field, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Communication; ∗Decision Making; ∗Mass Screening; ∗Risk; Consumer Participation [∗methods]; Patient Education as Topic;
Randomized Controlled Trials as Topic
MeSH check words
Humans
72Personalised risk communication for informed decision making about taking screening tests (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
